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Approximately 200 million men and 100 million women smoke worldwide. In
the United States, an estimated 25.9 million men (23.9 percent) and 20.7 million women
(18.1 percent) are smokers. The commencement of smoking at a young age is thought
to increase addiction liability, decrease the probability of successful cessation, and
correlate with a higher number of cigarettes smoked per day. Studies from the World
Health Organization indicate that between 80,000 and 100,000 children start smoking
every day worldwide. These statistics suggest that adolescence is a critical phase for
developing nicotine dependence. The work in this dissertation contributes to the further
xiii

understanding of this unique developmental period. Our research shows that various
aspects of nicotine dependence are both age- and sex-dependent. We observed age- and
sex-related differences in both nicotine reward and withdrawal models that imply a
heightened vulnerability for adolescents. In addition, we have investigated possible
behavioral and molecular mechanisms which may underlie the elevated vulnerability to
dependence. The data illustrate that while behavioral mechanisms only play a minor
role in the differences seen in reward and withdrawal, molecular mechanisms appear to
have a greater contribution. Specifically, increased nicotinic receptor function is likely
to be a substantial contributor to age-related disparities. In addition, nicotine is one of
the first and most commonly abused drugs in adolescence and is known to be a strong
predictor of subsequent alcohol and other drug abuse. Our research investigated the
effects of adolescent nicotine exposure on both nicotine and cocaine dependence in
adulthood. We found that exposure to nicotine during the early phase of adolescence
affects both nicotine reward and withdrawal in adulthood. Moreover, this exposure also
bears impact on other drugs of abuse such as cocaine. In summary, our data suggest
that early adolescence is the most critical period for becoming dependent to nicotine
and that early experimentation with nicotine may lead to enhanced vulnerability to
dependence on more illicit drugs of abuse. It is imperative that we understand why
adolescents have a heightened susceptibility to nicotine dependence so that better
smoking cessation therapies and prevention messages can be developed for this age
group.

GENERAL INTRODUCTION

A. Tobacco Smoking and Nicotine Dependence
In the United States, an estimated 25.9 million men (23.9 percent) and 20.7
million women (18.1 percent) are smokers (National Health Interview Survey (NHIS),
2005, National Center for Health Statistics). More importantly, smoking relateddiseases kill one in ten adults globally, or cause four million deaths. By 2030, if current
trends continue, smoking will kill one in six people (World Health Organization
Smoking Statistics 2002). Nicotine addiction is not only a problem for the adult
population. Surprisingly, over 6,000 teenagers begin smoking every day (American
Lung Association Statistics 2002). Moreover, 90% of adult smokers report their first
use of tobacco prior to age 18 (Chassin et al. 1990). Tobacco is reportedly the most
avoidable cause of disease and disability, yet less than 7% of smokers who attempt to
quit actually achieve more than one year of abstinence before they relapse (NIH Pub.
No. 98-4342, CDC Prevention and Health Promotion, 2005). Smoking is a significant
and preventable health concern that needs further attention so that sophisticated health
promotion campaigns and messages can be imparted to the public.
Nicotine is the primary addictive component in tobacco that acts on the brain to
produce both rewarding and aversive effects (Castane et al. 2005). Although nicotine
is known to reach the brain rapidly, it does not have long lasting acute effects due to its
short half-life of 1-2 hours (Viveros et al. 2006). This property of nicotine is likely to
contribute to its repeated and consistent use. In addition, environmental cues play an
1

important role in smoking addiction as well. Several human and rodent studies have
investigated the importance of cravings and contextual cues in smoking behavior using
conditioned place preference models. One study found that environmental cues related
to smoking activate certain CREB-related molecular pathways in the brain; therefore
eliciting the same effects as direct exposure to nicotine (Walters et al. 2005). Another
study examined brain activity in regions associated with attention, motivation, and
reward while participants viewed a series of pictures of smoking-related objects and
scenes (McClernon et al. 2005). Study participants provided self-reports of cravings
before, during, and after each session. Researchers found that smokers who reported a
greater urge to smoke following the period of abstinence also exhibited stronger brain
activity after viewing smoking-related images. In contrast, smokers who reported fewer
cravings displayed stable or decreased brain activity, despite viewing the same
smoking-related images after a period of abstinence (McClernon et al. 2005). These
differences may influence levels of cigarette craving following abstinence and may also
affect the impact of smoking cues. Smokers who experience a greater sensitivity to
smoking cues may have difficulty quitting smoking and may also be more prone to
relapse.
B. Adolescence and Smoking
Tobacco smoking at a young age is an increasing problem in the United States
and around the world. The rate of adolescent smoking among Americans has been
rising sharply since 1992 (Johnston et al. 1998). Moreover, the age of initiation for
smoking has also been declining (Johnston et al. 1998). The commencement of

smoking at a young age is thought to increase addiction liability, decrease the
probability of successful cessation (Colby et al. 2000; Kandel and Chen 2000), and
correlate with a higher number of cigarettes smoked per day (Taoli and Wynder 1991).
Studies from the World Health Organization provide evidence that around 50% of those
who start smoking in adolescence go on to smoke for 15 to 20 years (2003). These
statistics should indicate the critical nature of providing influential prevention messages
at an early age. The longer a child or teenager is prevented from smoking, the higher
the chance of preventing lifetime dependence.
Despite the fact that initial exposure to nicotine has been shown to be
unpleasant (Eissenberg and Balster 2000), many adolescents still go on to become
dependent on this drug despite the desire to quit. Even though adolescent tobacco
intake is thought to be lower than that of adults, this age group also experiences signs of
withdrawal such as cravings, nervousness, and the inability to concentrate (Rojas et al.
1998; Killen et al. 2001). In fact, adolescent smokers report frequent unsuccessful
attempts to quit due to cravings and withdrawal symptoms (Johnson 1982; Biglan and
Lichtenstein 1984). Certainly many factors are involved in an adolescent’s decision to
maintain a regular level of smoking. These include, but are not limited to, social
pressure, environment, stress, biological effects, reinforcing effects, and aversive
withdrawal symptoms. These studies show that further investigation is needed
regarding adolescent nicotine dependence and cessation therapies. Indeed, Colby et al.
(2000) wrote a review suggesting that the current methods and approaches to smoking
cessation in adolescence need additional attention since successful cessation rates are

modest. It is critical that we understand why this age group is particularly vulnerable to
nicotine dependence and addiction so that better prevention messages and smoking
cessation therapies can be developed.
The Transition of Adolescence
Adolescence is a critical decade of transition that occurs between a fully
dependent child and gaining independence as an adult. During this period, many
changes occur in a variety of areas such as physical growth, cognition, social skills,
physiology, and emotions. Since this developmental stage induces alterations of a
number of biological systems at one time, it is natural to assume that the adolescent will
experience an increased vulnerability to a wide range of biological and behavioral
problems. One of these issues is that of substance abuse. It has been shown that the
adolescent brain may be more susceptible to the effects of addictive substances such as
alcohol, nicotine, and cannabis among others (Spear 2000; Smith 2003; DiFranza 2007).
Furthermore, studies have also demonstrated that early use of any drug is a strong
indicator of regular drug use in adulthood (Toumbourou et al. 2005; Teeson et al. 2006).
These studies impart the importance of effectively framing prevention messages,
developing prevention strategies, and implementing useful public education tactics
before adolescents begin drug experimentation.
Adolescent Brain Development
The unique timing of adolescent brain development is thought to be a large
contributor to the heightened vulnerability to substance abuse. While the brain of a
young child is almost 95% of the size of an adult brain, there are many neuroanatomical

differences that yield dissimilar abilities to think and reason. In general, studies have
shown that the adolescent brain develops from back to front and from bottom to top;
thus the areas associated with emotion, instinct, and pleasure develop first. These areas
include the amygdala, ventral tegmental area (VTA), and nucleus accumbens (NAc).
Last to develop is the prefrontal cortex (PFC) which is responsible for critical thinking
and judgment. This imbalance leads to the activities which are often associated with the
hallmarks of adolescent behavior; that they tend to be impulsive and emotionally
driven, lack self-control and planned thinking, and demonstrate increased risk-taking
behavior. It is suggested that this maturation pattern contributes to an increased
propensity toward substance abuse at a young age.
Each brain region is susceptible to an immense amount of remodeling and
maturation. The PFC, in particular, undergoes many modifications during the
adolescent period. Volume of this region decreases in humans (Sowell et al. 1999) and
rats (van Eden et al. 1990). Furthermore, density of spines on pyramidal cells in the
human PFC decline (Mrzljak et al. 1990). On the other hand, dopaminergic (DA) input
to the PFC peaks during this phase (Lewis 1997; Brenhouse et al. 2008), as does the
quantity of DA transporters (Akbari et al. 1992). In addition to these increases in
dopaminergic input, an increase in the number of DA receptors has also been reported
(Seeman et al. 1987). While transformations of neural circuitry are not limited to the
DA system, these changes are thought to play a critical role in the rewarding and
reinforcing effects of many drugs of abuse, including nicotine.

In general, the adolescent brain goes through a vast amount of pruning, synapse
loss, and alterations of neurobiological pathways. It has been estimated that as many of
half of the average number of synapses are lost during adolescence (Rakic et al. 1994).
The function of this synaptic loss is not yet fully understood, but is assumed to have a
developmental purpose. One which has been suggested by Rakic et al. is that since
many of the synapses in adolescence are excitatory, the pruning serves to decrease
unnecessary excitatory stimuli to the brain. In addition, a variety of receptors (DA,
serotonin, GABA, acetylcholine) tend to be overproduced and subsequently pruned
during this period. (Lidow et al. 1991; Lidow and Rakic 1992). Collectively,
adolescence is a period of intense neurological development and many of the changes
which are ongoing during this period may play a role in subsequent drug abuse.
The Role of Gender in Nicotine Dependence
Gender and sex differences in response to the behavioral effects of drugs have
long been reported in humans and rodents (Bradley et el. 1968; Camp and Robinson
1988; Sircar and Kim 1999; Damaj 2001; Hughes 2006; Jones et al. 2006). However,
most of the published work is related to the adult. Indeed, female mice demonstrated
lower sensitivity to the acute effects of nicotine when tested in an acute thermal pain
model (Damaj 2001). Decreased nicotine sensitivity in females has also been shown in
several human studies (Jamner et al. 1998; Perkins et al. 1999). In reward paradigms,
adult female rats displayed a shorter latency to the first nicotine infusion in a selfadministration model and demonstrated faster acquisition of nicotine self-administration
behavior (Donny et al. 2000; Chaudhri et al. 2005). Pharmacokinetic and distribution

factors seem to play an important role in explaining these differences. Indeed,
Benowitz showed that women exhibit faster nicotine and cotinine metabolism as
compared to men (2006), possibly due to hormonal influences. This observation
suggests that females may smoke more cigarettes to obtain desired levels of nicotine in
the body resulting in a greater exposure to tobacco toxins and increased levels of
addiction. Neurobiological differences appear to contribute significantly to these sex
differences as well. Sex is a factor that influences many areas of the brain including
(but not limited to) memory, emotion, pain perception, neurotransmitter signaling, and
stress hormones. Structural and functional differences have been shown in the
hippocampus (Juraska 1991), amygdala (Hines et al. 1992), striatum and nucleus
accumbens (Becker 1999). Furthermore, there are unique differences in serotonin
(Carlsson and Carlsson 1988) and dopamine (Becker 1999) transmission. These
dimorphisms in signaling could lead to significant differences in behavioral responses,
particularly those involving addiction pathways.
Limited work on sex and gender differences in adolescent smoking has been
done. Even though adolescents have yet to reach full sexual maturity, some studies do
suggest differences in smoking behavior and nicotine sensitivity. Levin et al. (2003)
has shown that female rats which initiate nicotine i.v. self administration in young
adulthood exhibit higher nicotine intake as adults relative to rats that initiate self
administration in adulthood. Additionally, adolescent female mice have been shown to
voluntarily consume nicotine orally in a dose-dependent manner and to consume
significantly more than male adolescents (Klein et al. 2004). As with adults, social and

environmental factors are likely to contribute to progression from use to addiction in
adolescents, but there is undoubtedly a biological basis as well. Given that nicotine use
often begins in adolescent years, it is reasonable to speculate that developmental
changes are important contributors. Our studies aim to thoroughly investigate the
biological and pharmacological factors that are critical to nicotine abuse. It is important
to begin with the basic CNS physiological and pharmacological effects of nicotine in
order to fully understand the complexities of its abuse liability.
C. Molecular and Pharmacological Mechanisms Involved in Nicotine Dependence
Nicotinic Receptors
It is clear that nicotine has many central and peripheral effects which potentially
contribute to its addictive properties. Acute administration of nicotine elicits various
central responses including antinociception, hypoactivity, and hypothermia. Nicotine is
also known to have effects on other body systems including the cardiovascular (CV)
and gastrointestinal (GI) systems. Use of nicotine causes increases in heart rate and
blood pressure which is a concern for already hypertensive smokers (Benowitz 2003).
In the GI tract, nicotine is a known to cause smooth muscle relaxation via release of
nitric oxide (Irie et al. 1991). Nicotine exerts these physiological effects by binding to
nicotinic acetylcholine receptors (nAChRs) in the brain and the periphery. More
chronic nicotine exposure can lead to physiological dependence as a result of both the
rewarding and aversive properties induced by the drug.
Nicotinic acetylcholine receptors can be found in many locations throughout the
body. Neuronal receptors are found in the central nervous system (CNS) and the

peripheral nervous system (PNS), while neuromuscular receptors are found in
neuromuscular junctions. These ionotropic receptors are ligand gated ion channels
which are pentameric in structure meaning they are comprised of five subunits arranged
around a central pore. This central pore allows for the passage of cations such as
sodium, potassium, and calcium. Receptors can be a homomeric or heteromeric
composition of different subunits. The neuromuscular nAChR is composed of two α
subunits, one β, one δ, and either a γ or ε subunit, while the neuronal nAChR can
consistent of subunits ranging from α2- α10 and β2- β4 making them much more
heterogeneous. With such a wide variety of receptor subtypes, many different
pharmacological effects can occur upon nicotine administration.
The binding of a nicotinic agonist to the receptor causes a change in the
conformational state which leads to activation. That is, an agonist causes the gated ion
channel to open rapidly (activation) and then become inactive for a period of time
(desensitization) before returning to a resting state which is inactive, yet capable of
reactivation. Ligand-bound desensitization of the nicotinic acetylcholine receptor was
first characterized by Katz and Thesleff (Pitchford et al. 1992). This phenomenon is
often caused by prolonged or repeated exposure to a drug and results in decreased
responsiveness of that receptor to a stimulus. It can further lead to upregulation of
nAChRs in order to compensate for the lack of response to nicotine. This compensatory
mechanism is suggested to contribute to nicotine dependence and addiction (Changeux
et al. 1998; Buisson and Betrand 2002; Nashmi and Lester 2007).

Many of nicotine’s pharmacological effects are the result of activation of a
variety of nAChR subtypes. Although the precise mechanisms of these effects have not
been elucidated, recent research using genetic knockout models and pharmacological
ligands has contributed to further understanding. The majority of nAChRs in the CNS
contain either α4β2* heteromers or α7 homomers (Changeux et al. 1998). While it is
known that five α7 subunits compose the homomeric receptor, the α4β2* heteromers
can be composed of a variety of additional subunits including α5, α6, or β3 which lead
to diversity in receptor characteristics. Several studies have implicated the α4β2*
subtype, which is present throughout the mesolimbic dopamine pathway, in the
reinforcing effects of nicotine. Heteromeric α4β2* nAChRs are localized on
dopaminergic and GABAergic neurons in the VTA. Stimulation of dopaminergic
receptors often results in enhanced dopamine release, whereas the desensitization of
nAChRs on GABA neurons is thought to attenuate the GABA-mediated inhibitory drive
(Mansvelder et al. 2002; Cohen et al. 2005; Solinas et al. 2007). In addition, nicotine
interacts with nAChRs on glutamate neurons that regulate the activity of DA and
GABA neurons in the VTA. Taken together, this pattern of brain pathway activation is
likely to result in the enhanced rewarding and reinforcing effects which contribute to
nicotine addiction.
Indeed, preclinical studies in transgenic mice have shown that elimination of
either the α4 or β2 subunit attenuates the pharmacological and behavioral effects of

*

minor populations of α4β2 nAChRs may contain additional unknown subunits as defined by the asterisk
(Lukas et al. 1999)

nicotine (Picciotto et al. 1998; Marubio et al. 1999). Specifically, the β2 subunit has
been shown to be necessary for nicotine-induced conditioned place preference in mice
(Walters et al. 2006). In addition, targeted expression of β2 subunits in the VTA of β2knockout mice reinstates nicotine-induced DA release (Maskos et al. 2005). Data has
confirmed a role for this subtype in nicotinic withdrawal as well. Pharmacological
nicotine withdrawal studies demonstrated that utilizing the β2-selective antagonist,
dihydro-β-erythroidine (DHβE), resulted in anxiety-related behavior and elevations in
reward threshold, which are measures of affective signs of nicotine withdrawal (Damaj
et al. 2003; Bruijnzeel et al. 2004; Jackson et al. 2008).
Molecular Pathways Involved in Drug Dependence
One of the main goals in the field of nicotine research is to gain a better
understanding of the mechanisms which underlie nicotine dependence in order to
advance current smoking cessation therapies and prevention programs and reduce the
number of smoking-related illnesses and deaths. Even though many drugs exhibit
differing acute actions, the majority of drugs of abuse converge on similar reward
circuitry in the brain that has been shown to be involved in addiction and dependence.
The brain contains a specialized pathway, often referred to as the mesocorticolimbic
(MCL) reward pathway, which has been implicated in many of the rewarding and
reinforcing effects of drugs of abuse (Nestler 2001; Kobb and Le Moal 2001). This
pathway originates in the ventral tegmental area (VTA), near the base of the brain.
Neurons from this region send projections to target regions in the front of the brain,
most notably to the nucleus accumbens (NAc) (Nestler 2001; Hyman and Malenka

2001). Indeed, this circuit is a critical component of reward physiology in that animals
with lesions in these regions exhibit a loss of drug consumption (Robinson and Berridge
2001; Nestler 2004). Dopamine is the most common and essential neurotransmitter
involved in this pathway. Nicotine, in particular, is able to activate VTA dopaminergic
neurons directly via stimulation of nicotinic cholinergic receptors or indirectly via
stimulation of its receptors on glutamatergic neurons which then innervate dopamine
cells. In addition to nicotine, cocaine is also able to elevate dopamine production in
another manner. This drug, as well as other psychostimulants, inhibits the return of
dopamine to the VTA by blocking dopaminergic transporters; thus resulting in an
accumulation of dopamine in the junction (Nestler 2001).
The stimulation of nAChRs by pharmacological agents can lead to many
downstream consequences. One of the most prominent and readily released second
messengers following nAChR activation is calcium. Calcium can act downstream on a
number of targets including Ca2+/calmodulin-dependent protein kinases (CaM kinases)
and protein kinase A (PKA). This in turn leads to stimulation of the extracellular
signal-related kinase (ERK) pathway and activation of cAMP response element binding
protein (CREB) which has been implicated in drug addiction (Brunzell et al. 2003).
The transcription factor CREB is thought to play a major role in the rewarding
properties of many drugs of abuse. In particular, Walters et al. (2005) has shown that
activation of CREB is necessary for nicotine reward in adult mice as measured by
conditioned place preference testing. The involvement of CREB in nicotine withdrawal
remains more complicated. Chronic nicotine administration in mice results in decreased

CREB phosphorylation in the NAc but increased CREB phosphorylation in the
prefrontal cortex, while nicotine withdrawal increased CREB phosphorylation in the
VTA (Brunzell et al. 2003). In contrast, withdrawal from chronic nicotine in rats
decreased CREB, phosphorylated CREB, and CRE-DNA binding in the cortex and
amygdala (Pandey et al. 2001). The involvement of CREB in reward and withdrawal
pathways has been studied due to its connection with the formation of dopamine.
CREB can activate the enzyme, tyrosine hydroxylase (TH), which is required for
dopamine synthesis. When more dopamine is produced, reward is thought to increase
so the molecular players in this pathway are often examined when investigating drug
dependence. (See Figure 1 for schematic of pathway). We have focused on this
pathway since it remains the main mechanistic pathway which has been implicated
regarding nicotine addiction. Other pathways are still possible, but have not been wellcharacterized to date. We have chosen to begin our studies with the nAChRs since they
are the initial target of nicotine.
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Figure 1. Possible schematic pathway for the effects of nicotine.

D. Behavioral Models of Nicotine Dependence
Animal models allow researchers to investigate basic neurochemical
mechanisms of drug abuse, factors involved in drug dependence, and potential
treatment for these problems. Several behavioral models have been established in order
to consistently investigate the role of biological factors involved in nicotine
dependence. They have also been established due to the prohibitive factors often
associated with clinical studies such as cost, ethical concerns, and retaining an
appropriate number of subjects for follow-up visits. Four critical components of
nicotine dependence have been featured in animal models and are investigated in our
studies.
Reward and Reinforcement
Drugs of abuse elicit pleasurable effects which often contribute to their repeated
use and abuse. Rewarding properties of nicotine are most commonly assessed through
either self-administration models or conditioned place preference (CPP) models.
Conditioned place preference is a method which has been used extensively to assess the
acute rewarding effects of a drug by pairing it with a particular context (Bardo et al.
1995; Tzschentke 1998). Unlike other models, such as self-administration, this model
does not directly measure drug reinforcement; rather it is a measure of a preference for a
context which is associated with the drug stimulus. CPP models allow researchers to
assess rewarding effects of drugs without facing the technical challenges of establishing
self-administration in the mouse. Moreover, as demonstrated throughout the literature,
there is a reasonable concordance between drugs that produce a CPP and drugs that are

self-administered (Bardo and Bevins 2000) and data from this method serves to
compliment self-administration data. This model is well-established and several reports
have concluded that nicotine is able to induce CPP in rodents over a wide range of
doses and with various routes of administration (Le Foll and Goldberg 2005; Grabus et
al. 2006; Walters et al. 2006). This approach is advantageous because it has a short
duration, does not stress the animal with surgery or extensive training and tests the
animal in a drug-free state.
Nicotine Withdrawal
Rodent models have also been used to study nicotine withdrawal in humans
since this is a common reason given for relapse after smoking cessation (Piasecki et al.
2000). Nicotine infusion is accomplished by various routes of administration such as
osmotic mini-pumps, repeated injections, i.v. infusions, or through drinking water.
Withdrawal may be precipitated by pharmacological antagonists or spontaneous
removal of mini-pumps, promoting physical somatic signs (i.e. tremors, head shakes,
excessive grooming and ptsosis) and negative affective signs (i.e. anxiety, irritability,
and depressed mood), which are important determinants in nicotine dependence
(Hughes et al. 1991; Markou et al. 1998; Damaj et al. 2003; Cohen et al. 2005; Viveros
et al. 2006).
Acute Sensitivity
Nicotine exerts many pharmacological effects in the peripheral and central
nervous systems following acute administration. Initial sensitivity models are useful in
that they provide information on the immediate response to a drug. These initial effects

can provide insight into the biological systems on which the drug will act as well as any
individual differences that may be useful in identifying at-risk individuals before they
become addicted to certain drugs.
Our lab utilizes a well-characterized battery of tests which assess centrallymediated nicotinic effects. This battery can provide information concerning nicotine
potency, drug time-course, site of action, and receptor subtypes activated. Testing
includes two measures of antinociception, change in body temperature, and a measure
of locomotor activity. Commonly, nicotine induces increased antinociception,
hypothermia, and hypolocomotion in the mouse. Antinociception, or the lack of pain
response, is measured using both the tail flick and hot plate tests which are mediated by
spinal and supraspinal reflexes respectively.
Tolerance
Tolerance can be defined as the capacity of the body to become less responsive
to a particular substance; usually after chronic exposure to that substance. This aspect
of dependence is well-established with nicotine in rodents and humans (Stolerman et al.
1974; Marks et al. 1983; Perkins et al. 1994). In effect, if a person is tolerant to a drug,
such as nicotine, he will require more of that substance in order to achieve satisfactory
levels of reward or other pleasurable effects. This often leads to increased drug use and
can further levels of drug dependence. As with the withdrawal model, rodent tolerance
commonly uses mini-pumps to administer nicotine subcutaneously. Animals are then
challenged with various doses of nicotine to examine antinociceptive and hypothermic

effects. Tolerance models provide insight into which drugs are more likely to be
commonly abused due to reduced physiological effects after repeated exposure.
E. Animal Models of Adolescence
The period of adolescence offers a particular challenge when developing useful
animal models. A great deal of effort has gone into adapting appropriate adult animal
models to those which accurately reflect adolescent development. Adolescent animal
models, which have face (whether a test appears to be a good measure) and predictive
(degree to which inferences can legitimately be made) validity, have been designed in
order to better understand the biological factors which are involved in nicotine addiction
at this age. Limitations of these models often include deciding appropriate age
correlations and divisions as well as determining neurobiological correlations.
Adolescent models must also consider differing drug intake patterns of adolescents, the
influence of a lack of sexual maturity and assessing proper dosing regimens due to
pharmacokinetic differences in rodents.
Three developmental phases of rodent adolescence have been identified: early(PND 21-34), mid- (PND 35-46) and late- (PND 47-59) adolescence (Spear 2000;
Laviola 2003). These classifications are based on similarities in physical, social, and
biological development of both rodents and humans. While there are some species
differences and these classifications can vary slightly, these divisions have been
carefully researched and are considered the standard for research on the adolescent
period.

Behaviorally, many characteristics of the adolescent period are universal across
species. These traits are thought to bear adaptive and evolutionary value for all species
and will allow adolescents to properly transition into adulthood with all the required
skills. For example, much like human adolescents, adolescent rodents exhibit an
increase in the amount of social interaction time and a peak in play behavior (Primus
and Kellogg 1989). Another hallmark characteristic of adolescence is increased risk
taking. Indeed, over half of adolescents exhibit risk taking behaviors such as drunk
driving, sex without contraceptives, and use of illegal drugs (Arnett 1992). Similarly,
adolescent mice have been noted to exhibit hyperactive behavior in a novel environment
(Darmani et al. 1996) and a higher degree of novelty seeking as compared to adults
(Adriani et al. 1998).
In addition to behavioral consistencies, neural alterations in humans and rodents
appear to have correlations. There is a high degree of PFC remodeling noted in both
human adolescents (Jernigan et al. 1991) and in rats (van Eden et al. 1990). Moreover,
there are notable increases in dopaminergic input to the PFC (Kalsbeek et al. 1988) and
DA transporters (Akbari et al. 1992). These parallels in behavioral and neural
development have allowed researchers to develop and refine animal models of human
adolescence that allow for investigation of this critical period.
An important limitation of using animal models for adolescent research is that
the intake behavior of human adolescents is often different from that observed in the
adult. It is difficult to mimic a sporadic and unpredictable pattern of human adolescent
smoking behavior in an animal model which may limit validity of the model to some

degree. It is also important to consider pharmacokinetic differences between adults and
adolescents. Adolescents are known to have increased metabolism as compared to
adults (Trauth et al. 2000) which may require increasing the dose of nicotine so that
metabolite levels are consistent when testing is being performed and when comparing
data to that of adults.
F. Effects of Adolescent Nicotine Exposure
It is common for adolescents to first experiment with easily accessible drugs
such as alcohol and tobacco. Furthermore, it is also common for this type of drug use to
lead to the use of more illicit drugs of abuse. Indeed, nicotine is one of the first and
most commonly abused drugs in adolescence and is known to be a strong predictor of
subsequent alcohol and other drug abuse (Kandel et al. 1992). Several studies have
demonstrated that a minimal amount of smoking at a young age can lead to nicotine
addiction and dependence (Benowitz et al. 1994; DiFranza 2007).
Nicotine exposure during adolescence may have detrimental effects since this is
a period of high neuronal plasticity and brain development. Indeed, the level of
nAChRs can increase in the brain the day after the first exposure to nicotine (AbreuVillaca et al. 2003) implying a very rapid timeline for brain remodeling following drug
exposure. Furthermore, this nAChR upregulation persists at significant levels one
month after treatment (Abreu-Villaca et al. 2003). Moreover, animal studies have
demonstrated that adolescent nicotine exposure can cause alterations in the cholinergic,
serotonergic, dopaminergic, and noradrenergic systems (Kelley and Middaugh 1999;
Trauth et al. 1999) which all have roles in the reinforcing effects of other drugs of

abuse. Among these effects are neuronal cell death and changes in nicotinic receptor
expression (Trauth et al. 2000). Perhaps most important, the behavioral responses of
other drugs of abuse are known to be altered by adolescent nicotine exposure suggesting
a possible alteration in the reward system. Reductions in the rewarding value of abused
drugs are associated with increased self-administration, which implies that early
nicotine exposure might increase the risk for subsequent substance abuse problems.
Studies in Chapter 7 will examine the effects of nicotine on cocaine-induced
reward and sensitivity. Several groups have begun to explore the theory that adolescent
nicotine exposure may alter cocaine-induced effects later in development, but results
have been inconsistent to date. Kelley and Rowan (2004) found that C57BL/6J mice
demonstrated a decrease in cocaine-induced reward as measured by CPP after 25 days
of adolescent nicotine exposure. However, they also noted that this exposure led to an
increase in cocaine’s motor activating effects. In rats, a study by McQuown et al.
(2006) showed that a low dose of nicotine treatment for four days in adolescence
enhanced the reinforcing effects of cocaine in an i.v. self-administration model using a
FR1 schedule. Similarly, rats given nicotine from PND 35 to 44 demonstrated an
enhancement of cocaine-induced reward using a CPP paradigm (McMillen et al. 2005).
Based on the literature, it appears that nicotine exposure can lead to alterations in
cocaine sensitivity. However, studies have limited implications since measures have
not been evaluated under the same conditions and specific characterization of dose
effects, duration of exposure, and route of administration have not yet been

investigated. The reasons for this “cross-sensitivity” are yet to be fully understood, but
mechanisms such as dopamine neurotransmission could be involved.
G. Dissertation Objectives
The work in this dissertation addresses a three part hypothesis which will
contribute to the understanding of age-dependent differences in nicotine dependence.
To date, few studies have examined adolescence as a heightened period for
vulnerability to drug addiction. However, adolescent drug abuse is becoming a large
problem in the United States as teenagers are developing and maturing at a faster pace
than they did 10 to 20 years ago. More young teenagers and even pre-teens are
experimenting with drugs and this experimentation often begins with cigarette smoking.
These studies demonstrate a full characterization of nicotine dependence in various age
groups and both sexes, examine behavioral and molecular mechanisms which may
underlie these differences, and investigate the effects of adolescent smoking on future,
and perhaps long-term, drug abuse.
Overall, we hypothesized that vulnerability to nicotine in adolescence is due to a
shift in the balance between two key components of nicotine dependence, namely
reward and withdrawal, and that this shift is due to nicotine-induced, region-specific
changes in mesolimbic reward pathways. Furthermore, we predicted that nicotine
exposure in adolescence would lead to long lasting changes in nicotine behavior and
dependence as well as the rewarding mechanisms of other drugs of abuse.
Our first specific aim was to characterize the behavioral effects of nicotine using
two key measures of nicotine dependence: reward and withdrawal. These studies were

conducted in both the male and female sex. Based on preliminary data and previous
literature, we hypothesized that adolescents would demonstrate increased vulnerability
to nicotine dependence as compared to adults and that this vulnerability would be sexdependent.
The second specific aim was to examine the behavioral and molecular
mechanisms that may be involved in nicotine dependence pathways using both in vivo
and in vitro techniques. Our in vivo studies focused on characterizing levels of acute
sensitivity and tolerance to nicotine between adult and adolescent mice. After that, we
aimed our in vitro studies at the initial molecular target of nicotine: neuronal nicotinic
acetylcholine receptors. To this aim, we investigated changes in the function and
quantity of receptors using rubidium efflux assays and nAChR binding studies,
respectively. We also examined differences in levels of nicotine-induced dopamine
release from both ages; an important measurement of nicotine reward and
reinforcement. Our hypothesis was that adolescents would exhibit an increase in either
receptor number or function, if not both, which would contribute to our understanding
of increased nicotine addiction vulnerability.
The third and final specific aim was to examine whether adolescent nicotine
exposure resulted in long-lasting changes in levels of nicotine reward and withdrawal.
Both dose and duration of nicotine exposure were investigated since patterns of
exposure to nicotine have been shown to be an important factor in becoming dependent
(McNeill 1991). In addition to investigating this type of exposure on nicotine
dependence, we also examined the effects of adolescent nicotine exposure on cocaine

sensitivity. Rewarding effects, changes in locomotor activity, and locomotor
sensitization to cocaine were evaluated. For this aim, we hypothesized that exposure to
nicotine during early adolescence would cause persistent changes in both nicotine- and
cocaine-related behavior in adulthood. Specifically, perception of nicotine- and
cocaine-induced reward will be enhanced due to long-lasting effects on the
mesocorticolimbic reward pathway.
In summary, data from this study are the first to fully evaluate a battery of
nicotine dependence models in the same setting and conditions in different sexes and
ages. Furthermore, it investigated possible in vivo and in vitro mechanisms that could
be used in developing more effective smoking cessation strategies aimed at specific
audiences. Lastly, these studies provided new insight into the risks of adolescent
smoking. We have shown that experimentation with cigarette smoking may have longlasting effects on future drug dependence; thus demonstrating the importance of
effective prevention messages and smoking deterrents that should be made available to
youth.

BEHAVIORAL ASSESSMENT OF ADOLESCENT AND ADULT MICE IN
NICOTINE DEPENDENCE MODELS OF REWARD AND WITHDRAWAL

A. Introduction
While a few studies have investigated various aspects of nicotine dependence in
both adult and adolescent rodents, there is no comprehensive study examining multiple
features of nicotine dependence under the same experimental conditions. Since
behavioral effects of nicotine may vary with the paradigm employed, it is important to
conduct studies where various behavioral responses are evaluated in the same setting
and in parallel. The goal of this study was to fully characterize both age- and sexrelated differences in nicotine dependence models of reward and withdrawal in mice.
Nicotine elicits consistent rewarding effects and withdrawal signs which are
characteristic of dependence. Conditioned place preference (CPP) procedures have
been widely used as a measure of the potential rewarding effects of many different
psychoactive drugs (Bardo et al. 1995; Tzschentke 1998). Several groups have
established a nicotine-induced CPP in rodents (Biala et al. 2003; Walters et al. 2005).
Unlike other models, such as self-administration, this model does not directly measure
drug reinforcement; rather it is a measure of a preference for a context which is
associated with the drug stimulus. However, as demonstrated throughout the literature,
there is a reasonable concordance between drugs that produce a CPP and drugs that are
self-administered (Bardo and Bevins 2000) and data from this method serve to
complement self-administration data. CPP is advantageous because the animals are
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tested in a drug-free state and it does not require extensive surgical procedures which
are stressful to the animal.
In adult rodents, nicotine withdrawal has been well-characterized. Malin et al.
(1992, 1994) demonstrated increased numbers of abstinence signs following nicotine
cessation and following administration of nicotinic antagonists in rats. Similar effects
have been noted in mice. An increase in withdrawal signs was reported in a number of
studies (Isola et al. 1999; Damaj et al. 2003) as well as hyperalgesia (Damaj et al. 2003)
upon both spontaneous withdrawal (no antagonist) and precipitated withdrawal
(antagonist) testing in mice of different genetic backgrounds.
Only a limited number of studies have investigated these two aspects of nicotine
dependence in the adolescent rodent. Vastola (2002) reported that in the CPP paradigm
only rats conditioned during adolescence showed preference to nicotine; however, to
date, there have been no studies which have investigated this model of reward in the
mouse. Adolescent nicotine withdrawal has been examined in a rat model as well.
O’Dell et al. (2006) reported decreased somatic signs in the adolescent rat as compared
to the adult rat. In addition, Shram et al. (2006) demonstrated that early adolescent rats
do not develop avoidance to saccharin solutions which have been paired with nicotine
while adults do develop this avoidance. The present study will examine both reward
and withdrawal paradigms in the mouse model in order to extend the current findings.

B. Methods
General methodology for all studies
Choice of Age, Sex, and Strain
As previously mentioned in Chapter 1, adolescence in the rodent is defined
using various factors informative of developmental transitions in human adolescents.
Our studies will use the standard divisions that have been defined by previous studies in
rodents: early- (PND 21-34), mid- (PND 35-46) and late- (PND 47-59) adolescence
(Spear 2000 and Laviola 2003).
ICR mice were used in all studies. This strain is an outbred stock with a fast
growth rate which is conducive to our experimental procedures. It has been used
extensively in toxicology and pharmacology studies. All animals were ordered from
Harlan Laboratories (Indianapolis, IN). We are aware that litter effects, particularly in
the adolescent age, may present confounds in our data analysis. To ensure that this was
not the case, we requested that our animals were obtained from different litters. We
also ordered animals at different times to minimize this issue. Animals were maintained
in an American Association for Accreditation of Laboratory Animal Care approved
facility and the study was approved by the Institutional Animal Care and Use
Committee of Virginia Commonwealth University.
This chapter focuses on the behavioral characterization of nicotine dependence
in both male and female mice. Even though sex differences were apparent, further
studies focused solely on the male sex. We felt that it was beyond the scope of this

project to properly examine the changes in hormonal levels during adolescence and
decided to center our research on male mice so that we could fully characterize this sex.
Drugs
(-)-Nicotine bitartrate and mecamylamine hydrochloride were purchased from
Sigma Chemical Company (Milwaukee, WI). All doses are expressed as free base.
Nicotine-induced conditioned place preference
Place conditioning boxes consisted of two distinct sides (20 cm X 20cm X 20
cm). A partition separated the two sides with an opening that allowed access to either
side of the chamber, and this partition could be closed off for pairing days.
Handling habituation: On Wednesday – Friday of the week prior to the start of the
place conditioning procedure, mice in the CPP studies were handled once per day for
approximately two min each. Handling experience plays an important role in the ability
of nicotine to produce a conditioned place preference (Grabus et al. 2006).
Preconditioning Phase: On day 1, animals were placed in the boxes and allowed to
roam freely from side to side for 15 min, and time spent in each side was recorded.
These data were used to separate the animals into groups of approximately equal bias.
Conditioning Phase: Animals were paired for 20 min with the saline group receiving
saline in both sides of the boxes and drug groups receiving nicotine (0.05, 0.1, 0.5, 0.7
or 1 mg/kg) on one of the sides and saline on the opposite side. Drug-paired sides were
randomized among all groups. Conditioning lasted for 3 days, with animals in the drug
group, receiving drug each day.

Test Phase: On the test day, no injections were given. Time spent on each side was
recorded, and data were expressed as time spent on drug-paired side minus time spent
on saline-paired side. A positive number indicated a preference for the drug-paired
side, while a negative number indicated an aversion to the drug-paired side. A number
at or near zero indicated no preference for either side.
Mecamylamine-Precipitated Withdrawal Studies
Naïve mice were implanted with osmotic mini-pumps filled with either saline or
nicotine (48 mg/kg/day) on day 1. The mini-pumps were surgically implanted s.c.
under sterile conditions with pentobarbital anesthesia (35 mg/kg, i.p.). An incision was
made in the back of the animals, and a pump was inserted. Animals were sutured and
allowed to recover before being returned to their home cages. On the morning of day 8,
mice were injected s.c. with 2.0 mg/kg of mecamylamine, a nicotinic antagonist. Ten
minutes following injection with the antagonist, mice were tested for withdrawal signs
in the following manner: 5 min for anxiety-like behavior (on the elevated plus maze
described below), 20 min observation of somatic signs (paw tremors, head shakes,
backing, body tremors, ptosis), hyperalgesia (hot-plate test), and 30 min in locomotor
activity chambers.
Elevated plus maze. The EPM is an apparatus consisting of two closed arms and two
open arms. The mouse is placed in the center of the maze and allowed to roam freely
between the open and the closed arms for 5 min. The number of seconds the mouse
spends in the open arms is counted by a counting device attached to beams located on

both arms and in the middle of the plus maze. Scores are based on time spent in the
open arms as an indication of anxiety-like behavior.
Hot-Plate Test. Supraspinal antinociception was assessed by the hot-plate method.
Briefly, each mouse was injected s.c. with nicotine and tested 5 min after injection.
Mice were placed on a hot plate (Thermostat Apparatus, Columbus, OH) maintained at
55˚C. Latency to reaction time (jumping or paw licking) was recorded. A control
response (8-12 sec) was determined for each mouse before treatment and test latency
was determined after drug administration. A maximum latency of 40 sec was imposed.
Antinociceptive response was calculated as %MPE, where %MPE = [(test - control)/(40
- control) x 100].
Locomotor Activity. Mice were placed into individual Omnitech photocell activity
cages (Columbus, OH; 28 x 16.5 cm) 10 min after s.c. administration of nicotine.
Interruptions of the photocell beams (two banks of eight cells each) were then recorded
for the next 30 min. Data are expressed as number of photocell interruptions.
Spontaneous Withdrawal Studies
Naïve mice were implanted with osmotic mini-pumps filled with either saline or
nicotine (48 mg/kg/day) for 7 days (as described previously). On day 8, mice were
lightly anesthetized using ether and mini-pumps were removed. A small incision was
made on the back of the neck in order to remove the mini-pump and the wound was
closed with a suture. Twelve hours following removal of the mini-pump, mice were
evaluated with the same withdrawal measures described above.
Repeated Injection Withdrawal Model

Naïve mice were injected s.c. with 2.0 mg/kg of nicotine three times a day for
four days (injections were given at 8:00am, 12:00pm, and 4:00pm). On the morning of
day 5, mice received 2.0 mg/kg of mecamylamine s.c. and were evaluated 10 min later
in the same withdrawal measures previously described.
Statistical analysis
Statistical analysis of all behavioral studies was performed with mixed-factor
ANOVA with post-hoc Tukey’s test when appropriate. P-values of <0.05 were
considered to be statistically significant.
C. Results
Nicotine-induced Conditioned Place Preference
The ability of nicotine to produce an effect in conditioned place preference in
both ages and sexes is presented in Fig. 2. As expected, adult and early adolescent
animals injected with saline in both chambers, showed no preference for either
chamber. Compared to saline controls, male adult mice conditioned with the
intermediate dose of 0.5 mg/kg nicotine showed a significant place preference. There
were no significant preferences seen with lower doses of 0.05 or 0.1 mg/kg, and the
effect disappeared at the higher doses of 0.7 and 1.0 mg/kg nicotine. In contrast,
nicotine induced a significant place preference in adolescent mice at low doses of
nicotine (0.05 and 0.1 mg/kg) as well as at the 0.5 mg/kg dose. Similar to the adult
mice, the effect disappeared at the higher doses of 0.7 and 1.0 mg/kg nicotine.
In female mice, a 2 x 2 ANOVA (age x dose) revealed a significant interaction.
Upon further post-hoc analysis, it was found that compared to saline controls, adult

mice conditioned with the doses of 0.7 and 1.0 mg/kg nicotine showed a significant
place preference; whereas no significant preferences developed with lower doses of 0.1
or 0.5 mg/kg. In contrast, nicotine produced a significant CPP in adolescent mice at the
intermediate dose of 0.5 mg/kg; an inactive dose in adults. Moreover, adolescents
experienced CPP at a narrow dose range and the dose-response curve is shifted to the
left. Locomotor activity was also recorded and did not differ between the age groups.
(Adults: 988 ± 32, Adolescents: 1012 ± 44).
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Figure 2. Nicotine-induced conditioned place preference in male and female mice.
Adult (PND 70) and early adolescent (PND 21) were injected s.c. with various
doses of either saline or nicotine. Positive scores indicate a preference for nicotine
while negative scores are indicative of aversion to the drug. Scores at or near zero
indicate neither preference nor aversion. Each bar represents the mean ± SEM of
8-9 mice. *p<0.05 from saline group.
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Age-Dependent Acquisition of Conditioned Place Preference
One possible explanation for the enhanced preference seen in adolescent mice is
the rate of CPP acquisition. It has been suggested that adolescents have an increased
rate of learning as compared to adults. To examine this possibility, we conducted a
CPP study in which subsets of mice were conditioned with nicotine for either 1, 2, or 3
sessions and were subsequently tested for CPP the following day using a dose of 0.5
mg/kg nicotine since this dose was active in both ages in previous experiments. This
experiment was only performed in male mice as this sex was determined to be the focus
of our studies. Figure 3 shows the results of this study which demonstrate that both
adult and adolescent mice acquired a significant preference for nicotine after three
conditioning sessions. Neither one nor two sessions elicited a preference for either
compartment.

35
Adult-Saline
Adult-Nicotine
Adolescent-Saline
Adolescent-Nicotine
150

Acquisition of Conditioned Place Preference

*
*
100

50

0

-50
1 Session

2 Sessions

3 Sessions

# of Conditioning Sessions

Figure 3. The rate of CPP acquisition in adult and adolescent mice. Male ICR
were conditioned for 1, 2, or 3 sessions with 0.5 mg/kg nicotine and were
subsequently evaluated for nicotine-induced preference. Bars represent the mean ±
SEM of 6-8 mice. * p<.05 as compared to respective saline control.
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Precipitated Withdrawal Model
Males
Mecamylamine challenge to animals implanted with nicotine-filled mini-pumps
represents a highly reproducible precipitated withdrawal syndrome. Measures of
precipitated withdrawal in adult and adolescent male mice are shown in Fig. 4. Two
types of withdrawal signs were evaluated: physical (somatic signs, hyperactivity, and
hyperalgesia) and affective (anxiety-like behavior in the plus maze). In males,
adolescent mice displayed fewer withdrawal signs in all four measures as compared to
adults. Adolescents displayed a lower number of somatic signs (Fig. 4a) as compared to
adults. In the elevated plus maze (Fig. 4b), only adults displayed withdrawal as
indicated by a significant decrease in time spent in the open arms of the maze, an
indication of anxiety-like behavior. Similarly, in the hot-plate test (Fig. 4c) and
locomotor activity test (Fig. 4d), only adult mice displayed hyperalgesia and
hyperactivity respectively.
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Figure 4. Mecamylamine-precipitated withdrawal in adult (PND 70) and
adolescent (PND 21) male mice. Mice were chronically infused with nicotine at 48
mg/kg/day or saline for 7 days. On day 8, mice were injected with 2.0 mg/kg of
mecamylamine or saline s.c. to precipitate withdrawal and evaluated in four tests:
(a) somatic signs, (b) elevated plus maze, (c) hot plate analgesia test, and (d)
locomotor activity. * p<0.05 from saline group and #p<0.05 from adult nicotine
treatment. Each point represents the mean ± S.E. of 12 mice. MP=mini-pump.
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Females
Female mice displayed an opposite trend in withdrawal. In somatic signs (Fig
5a), results showed that there was a significant 2 way interaction (age x treatment),
indicating that both ages demonstrated significant withdrawal signs, but the intensity of
withdrawal was age-dependent. Indeed, adolescent females displayed significantly
higher somatic signs as compared to adults as determined through post-hoc analysis. In
the hot plate analgesia test (Fig. 5c), there was no significant interaction. However,
adolescents with nicotine mini-pumps displayed a significant attenuation in analgesia
upon treatment with mecamylamine, indicative of withdrawal, while adults failed to do
so (p=.08). Adolescents also showed significant withdrawal in hyperactivity (Fig. 5d),
while adult mice did not, but no significant interaction was found.
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Figure 5. Mecamylamine-precipitated withdrawal in adult (PND 70) and
adolescent (PND 21) female mice. Mice were chronically infused with nicotine at
48 mg/kg/day or saline for 7 days. On day 8, mice were injected with 2.0 mg/kg of
mecamylamine or saline s.c. to precipitate withdrawal and evaluated in four tests:
(a) somatic signs, (b) elevated plus maze, (c) hot plate analgesia test, and (d)
locomotor activity. * p<0.05 from saline group and #p<0.05 from adult nicotine
treatment. Each point represents the mean ± S.E. of 12 mice. MP=mini-pump.
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Spontaneous Withdrawal Model
Males
While the mecamylamine-precipitated withdrawal model revealed clear
differences between adolescents and adults, the question arises as to whether
adolescents and adults have identical sensitivities to mecamylamine. In order to
investigate this possibility, spontaneous withdrawal studies were carried out. In the
spontaneous withdrawal model, mini-pumps were removed on day 8 and no drugs were
used to elicit withdrawal behaviors. As shown in Fig. 6, both adult and adolescent male
mice displayed a significant increase in the number of somatic signs after chronic
treatment with nicotine; however, adolescent mice had significantly fewer of these signs
as compared to adults (Fig. 6a). Results were similar for the hot-plate (Fig. 6c) and
locomotor activity (Fig. 6d) tests which confirmed the data from the precipitated
withdrawal model. Only adult mice displayed affective withdrawal signs in the
spontaneous model as shown by the decrease in time spent in the open arms of the
elevated plus maze (Fig. 6b).
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Figure 6. Spontaneous withdrawal in adult (PND 70) and adolescent (PND 21)
mice. Male mice were chronically infused with nicotine at 48 mg/kg/day (dark
bars) or saline (cross-hatched bars) for 7 days. Twelve hours after mini-pumps
were removed, mice were tested for: (a) somatic signs and (b) elevated plus maze.
Each point represents the mean ± S.E. of 12 mice. * p<0.05 from saline group and
# p<0.05 from adult nicotine treatment. MP = mini-pump
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Females
As shown in Fig. 7a, females also exhibited significant somatic signs of
withdrawal, but adolescents had a significantly greater number of signs than did adults.
Furthermore, only adolescents displayed significant hyperalgesia and hyperactivity
during the withdrawal testing (Fig. 7c and 7d) which is consistent with data from
precipitated withdrawal studies.
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Figure 7. Spontaneous withdrawal in adult (PND 70) and adolescent (PND 21)
female ICR mice. Mice were chronically infused with nicotine at 48 mg/kg/day
(grey bars) or saline (open bars) for 7 days. Twelve hours after mini-pumps were
removed, mice were tested for: (a) somatic signs and (b) elevated plus maze (c) hot
plate analgesic test, and (d) locomotor activity. Each bar represents the mean ±
S.E. of 12 mice. * p<0.05 from saline group and # p<0.05 from adult nicotine
treatment. MP = mini-pump
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Repeated Injection Withdrawal Model
Males
One of the limitations of mini-pumps is the inability to alter drug delivery
during the exposure period, particularly when adolescents and adults are gaining weight
at different rates. Therefore, we replicated the above studies with repeated injections
based on the daily weights of the animals. The repeated injection model confirmed our
previous withdrawal results with mini-pumps as shown in Fig. 8. Hyperactivity is
demonstrated only by adult mice in the locomotor activity test (Fig. 8d). Furthermore,
in the hot-plate test (Fig. 8c), adult mice displayed hyperalgesia while adolescent mice
failed to exhibit this effect. In the affective sign of withdrawal, only adults exhibited
anxiety-like behavior in the elevated plus maze (Fig. 8b).
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Figure 8. Withdrawal following repeated injections in adult (PND 70) and
adolescent male (PND 21) mice. Mice were injected with saline or 2.0 mg/kg of
nicotine s.c. three times a day for four days. Sixteen hours following the last
injection, mice were injected with 2.0 mg/kg of mecamaylamine or saline s.c. and
evaluated for: (a) somatic signs (b) elevated plus maze (c) hot plate analgesia and
(d) locomotor activity. Each point represents the mean ± S.E. of 10 mice. * p<0.05
from saline group.
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Females
The repeated injection model was also conducted in female mice as shown in
Fig. 9. As with the precipitated model, adolescent mice displayed a significant increase
in somatic signs as compared to adults (Fig. 9a). Unexpectedly, in the elevated plus
maze (Fig. 9b), adolescents showed a decrease in anxiety-like behavior while adults had
no change from control animals. In the hot-plate test, adolescent mice displayed
significant hyperalgesia (Fig. 9c) while adults showed no indication of withdrawal.
Surprisingly, no hyperactivity was seen in the locomotor activity test (Fig. 9d). The
overall intensity of this test was lower than normal which may be attributable to stress
induced by the multiple injections used in this model.
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Figure 9. Withdrawal following repeated injections in adult (PND 70) and
adolescent (PND 21) female ICR mice. Mice were injected with saline or 2.0 mg/kg
of nicotine s.c. three times a day for four days. Sixteen hours following the last
injection, mice were injected with 2.0 mg/kg of mecamaylamine or saline s.c. and
evaluated for: (a) somatic signs and (b) elevated plus maze (c) hot plate analgesic
test, and (d) locomotor activity. Each bar represents the mean ± S.E. of 10 mice.
* p<0.05 from saline group and # p<0.05 from adult nicotine treatment.
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D. Discussion
There is little question that social and environmental factors play significant
roles in initiation of tobacco use. While these factors contribute to progression from use
to addiction, there is undoubtedly a biological basis as well. Given that nicotine use
often begins in adolescent years, it is reasonable to speculate that developmental
changes are important contributors. These changes may impact important aspects of
nicotine dependence such as reward and the magnitude of withdrawal. The goal our
first study was to investigate both age- and sex-related differences in nicotine
dependence using behavioral rodent models. From our results, it appears that reward
and withdrawal are two key components of adolescent nicotine dependence which may
have implications in adolescent vulnerability to nicotine addiction. For simplicity, the
following discussion will discuss age differences in each sex individually before
addressing the issue of sex differences.
Our data show that adolescent male mice are more sensitive to nicotine’s
rewarding effects than adult male mice in the CPP model. Several factors could explain
the differences in nicotine potency; that is to say that different concentrations of
nicotine may result in certain effects at one age while not at another age. One such
factor is differences in motor function between adult and adolescent mice. However,
locomotor activity data suggests no differences in motor function (Figure 10).
Alternatively, the conditioning session and duration might have been optimal for
adolescents but not for adults at a low dose of nicotine. Varying the duration of the
sessions may alter the development of place preference at lower doses in adults and
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adolescents. However, previous studies have tested a variety of conditioning sessions
and durations and have not identified this as a confounding factor (Belluzzi et al. 2004).
An additional factor when using CPP involves contextual learning and memory. It is
possible that adolescents display increased learning as compared to adults. Our
acquisition study (Figure 3) rules out this possibility in that we showed no difference in
the rate of CPP acquisition between adults and adolescents. Finally, it is possible that
pharmacokinetic differences between adult and adolescent rodents could explain the
different potencies. If this is the case, adolescents are reported to have increased
metabolism (Trauth et al. 2000); this however would translate into a decrease, not an
increase, in the rewarding effect of nicotine. Given that metabolism is not a largely
contributing factor, our data suggest that pharmacological factors are responsible for the
enhanced rewarding effect from nicotine conditioning in adolescent rodents.
Data from our withdrawal study showed that male adolescent mice displayed
decreased withdrawal signs in three different somatic measures and one affective
measure. However, results should be interpreted with caution because of several
possible confounding factors. Although the use of mini-pumps allows for a minimal
amount of stress to be placed on the animal, it will not take into account the fact that
adolescent animals display a growth rate much faster than that of adults. Since the dose
of nicotine is based on body weight at the beginning of the experiment, it could be
argued that the younger mice are not receiving a dose of nicotine that is consistent with
that of the adult. For this reason, we also evaluated withdrawal using a repeated
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injection model that was based on the animal’s daily weight. In both studies it was
found that withdrawal signs were attenuated in adolescent animals.
Another factor that could be playing a role is that adults and adolescents could
have differing sensitivities to mecamylamine. In order to investigate this possibility, we
conducted a spontaneous withdrawal experiment in which mecamylamine was not used
to precipitate withdrawal. Again, similar and consistent results were found in this
study with adolescent animals displaying a decrease in the intensity of withdrawal
signs. Collectively, these studies suggest a minor role for the two above factors in the
withdrawal differences.
Overall, our data have significant implications. First, we have shown that
adolescents, when given the same level of nicotine as adults, express withdrawal signs
which are an important observation from a clinical perspective. Although the intensity
of nicotine withdrawal is less than that of the adult, this finding confirms work in
clinical studies showing that adolescent smokers exhibit signs of nicotine dependence.
It is also interesting to note that adolescent smoking behavior is not consistent with that
of adults and it is likely that their actual nicotine intake is lower. In this regard it is
difficult to make a valid assessment of how much withdrawal symptoms contribute to
dependence for adolescents. In addition to withdrawal signs, we have shown that
during adolescence positive rewarding effects of nicotine are enhanced in the male sex.
It could be argued that these positive effects contribute more to the enhanced
vulnerability to nicotine addiction. During the adolescent period there is a high desire
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for immediate positive reinforcement without proper assessment of risk which suggests
that adolescence may be a critical period for the development of nicotine addiction.
Female studies in nicotine dependence showed characteristically different results
than those from male studies. It is well known that the incidence of smoking among
women has changed dramatically over the past few decades. Moreover, it has become
clear in recent times that females experience considerable difficulty in quitting smoking
(Perkins et al. 1999; Field and Duka 2004; Leventhal et al. 2007). The goal of this
study was to identify the properties of nicotine that might explain differences in
adolescent and adult female behavioral responses to this drug.
The results from our CPP study show age-dependent differences in nicotineinduced reward sensitivity in females. Significant preference was observed at a dose of
0.5 mg/kg in adolescent mice while adult mice displayed rewarding effects at 0.7 and
1.0 mg/kg demonstrating differences in the range of preference. It appears that
adolescents display an enhanced sensitivity to nicotine’s rewarding effects at lower
doses than adults. However, this may only play a minor role in overall dependence due
to the narrow dose-response curve. Once again, nicotine-induced differences in
locomotor activity between adult and adolescent mice may cause the observed
differences. However, as stated previously, data for locomotor activity were collected
and no significant differences were found (Figure 11). It is also possible that
pharmacokinetic differences between adult and adolescent rodents could explain the
different potencies. It is well-established in adult rodents that sex and age can affect
nicotine metabolism. Although some reports suggest that adolescents have an
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increased metabolism (Adriani et al. 2002; Klein et al. 2004), our data suggest that this
change in metabolism does not play a major role in the differences seen in our studies
since the acute effects are not consistent across all measures (this is will be further
discussed in Chapter 3).
Nicotine withdrawal studies in the female sex indicate that adolescents have
increased physical withdrawal symptoms (somatic signs, hyperalgesia, and
hyperactivity) as compared to adult females. However, no differences in affective
withdrawal signs (anxiety-like behavior) were observed. This enhanced withdrawal
intensity is likely to adversely affect adolescents who are attempting to quit smoking.
In agreement with our rodent studies, clinical findings report that women are less likely
to quit smoking successfully due to high withdrawal effects (Leventhal et al. 2007). For
these reasons, treatment strategies that focus on alleviating these negative withdrawal
symptoms are likely to be the most effective in female smokers, particularly in
adolescents. A possible cause for this increase in withdrawal intensity is the higher rate
of metabolism in adolescents (Trauth et al. 2000), however, as previously stated,
metabolism is not likely to be the most important contributor to this difference. In
addition, data has shown that sex hormones are able to modulate the effects of nicotine
which may contribute to differences seen between male and female rodents (Damaj
2001). However, this possibility is also unlikely given that female adolescents are not
sexually mature at this stage of development.
The current study, as well as previous research (Trauth et al. 1999; Adriani et al.
2004; O’Dell et al. 2006; Shram et al. 2006) suggests that adolescence is a critical
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period for vulnerability to nicotine dependence in both male and female adolescents.
Nicotine dependence is based on the balance between the positive and negative effects
of nicotine. Certain theories of nicotine dependence have suggested that some people
smoke in order to cope with negative withdrawal symptoms, while others smoke for
reward and pleasure. Our data suggest that negative withdrawal signs are more strongly
associated with nicotine dependence than rewarding effects in female adolescents.
However, in males it appears that reward may play a larger role. Development of
treatment strategies that are tailored to youth are needed in order to combat the growing
problem of adolescent smoking. It is important to note that data from this study show
that an opposite association was seen in males and females suggesting that smoking
cessation therapies will not necessarily be equally efficacious for each sex at an early
age. Furthermore, a comparison of adult withdrawal reveals that males exhibit a
greater intensity of nicotine-induced withdrawal signs as compared to females, but also
experience enhanced positive and rewarding effects of nicotine.
Taken together, these studies have important implications for the mechanisms
of nicotine dependence in adolescence. Several behavioral and molecular mechanisms
may explain these differences. Differences in activation, function, and regulation of
various targets of nicotine, such as nAChRs, are likely to be involved. We decided to
investigate these possibilities by using both in vivo and in vitro approaches.
It is possible that there are innate differences in the acute sensitivity to nicotine
between adults and adolescents. Furthermore, differences in tolerance could help to
explain our behavioral observations. Therefore we examined these two aspects of
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dependence using in vivo models. Additionally, it is possible that functional properties,
distribution, and number of nAChRs differ between adult and adolescent rodents. It is
also possible that nicotine exposure during early adolescence is altering the neuronal
pathways which are still developing in young animals. For example, the dopaminergic
system is still developing during the adolescent period (Spear 2000). Many studies
have shown that upon activation of nAChRs, dopamine is released and can act to
modulate rewarding effects (Wonnacutt 1997). It is possible that levels of dopamine
release differ in the adult and adolescent, a factor that may contribute to the differences
seen in levels of reward using the CPP model. In order to answer these questions, we
took an in vitro approach and used a variety of molecular assays to investigate these
targets.
Indeed, current research implies that adolescence is a critical period for
acquiring nicotine dependence. Since adolescent smokers have been shown to have a
more difficult time quitting than smokers who begin in adulthood (Colby et al. 2000), it
is critical to understand why this timeframe is especially vulnerable to addiction. A
more in depth investigation of these behavioral and molecular mechanisms will be
further addressed in Chapters 3 and 5.

IN VIVO PHARMACOLOGICAL MECHANISMS INVOLVED IN NICOTINE
DEPENDENCE
A. Introduction
Data from Chapter 2 indicated that two key components of nicotine dependence,
namely reward and withdrawal, have differing pharmacological profiles in early
adolescent and adult mice. Various mechanisms could be involved in these age
differences and determining those which play the greatest role will allow a more
comprehensive understanding of this behavior. To this aim, we have examined two
possible in vivo pharmacological mechanisms which are known to be involved in drug
dependence: acute sensitivity and tolerance.
Acute sensitivity models are useful in that they provide information on the
immediate response to a drug and could reflect differences in nicotine receptor
activation and function. In addition, these initial effects can provide insight into the
biological systems on which the drug will act as well as any individual differences that
may be useful in identifying at-risk individuals before they become addicted to certain
drugs.
Tolerance studies usually allow the detection of the capacity of the body to
become less responsive to a particular substance; usually after chronic exposure to that
substance and could reflect differences in the receptor regulation and consequent signal
transduction mechanisms after chronic exposure to a drug. Tolerance is likely to
contribute to repeated nicotine use and lead to physical dependence. If adolescent and
adult rodents display differences in levels of tolerance or immediate drug sensitivity,
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this will provide insight into the underlying behavioral differences in reward and
withdrawal models.
Previous studies have shown that nicotine administration elicits several
consistent acute effects including hyperalgesia (Marubio et al. 1999), hypoactivity
(Clarke 1990; Dwoskin et al. 1999), and hypothermia (Knox et al. 1973). However,
tolerance to these initial effects has also been well-documented. Specifically, rodents
exposed to chronic nicotine administration show reduced responsiveness to analgesic
assays (Damaj and Martin 1993), hypothermia and locomotion (Robinson et al. 1996).
It is important to consider these two aspects in explaining variations in levels of nicotine
dependence between age groups.
B. Methods
Acute Sensitivity
Mice were given s.c. injections of nicotine and tested in four pharmacological
tests: analgesia (two assays, tail-flick and hot-plate), locomotor activity and
hypothermia.
Tail-Flick Test. Spinal antinociception was assessed by the tail-flick method of
D’Amour and Smith (1941). Briefly, mice were lightly restrained while a radiant heat
source was directed onto the upper portion of the tail. A control response (2-4 sec) was
determined for each mouse before treatment, and test latency was determined after drug
administration. In order to minimize tissue damage, a maximum latency of 10 sec was
imposed. Antinociceptive response was calculated as percent maximum possible effect
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(% MPE), where %MPE = [(test-control)/(10-control)] x 100. The mice were tested 5
min after injection of nicotine.
Hot-Plate Test. Supraspinal antinociception was assessed by the hot-plate method.
Briefly, each mouse was injected s.c. with nicotine and tested 5 min after injection.
Mice were placed on a hot plate (Thermostat Apparatus, Columbus, OH) maintained at
55˚C. Latency to reaction time (jumping or paw licking) was recorded. A control
response (8-12 sec) was determined for each mouse before treatment and test latency
was determined after drug administration. A maximum latency of 40 sec was imposed.
Antinociceptive response was calculated as %MPE, where %MPE = [(test - control)/(40
- control) x 100].
Locomotor Activity. Mice were placed into individual Omnitech photocell activity
cages (Columbus, OH; 28 x 16.5 cm) 10 min after s.c. administration of nicotine.
Interruptions of the photocell beams (two banks of eight cells each) were then recorded
for the next 10 min. Data are expressed as number of photocell interruptions.
Body Temperature. Rectal temperature was measured by a thermistor probe (inserted
24 mm) and digital thermometer (Yellow Springs Instrument Co., Yellow Springs, OH).
Readings were taken just before and at 30 min after the s.c. injection of nicotine. The
difference in rectal temperature before and after treatment was calculated for each
mouse. The ambient temperature of the laboratory varied from 21-24°C from day to
day.

58
Tolerance studies
Mice were implanted with Alzet osmotic mini-pumps (model 2002- Alza
Corporation, Palo Alto, CA) filled with either (-)-nicotine (48 mg/kg/day) or sterile
physiological saline solutions. The mini-pumps were surgically implanted s.c. under
sterile conditions with pentobarbital anesthesia (35 mg/kg, i.p.). An incision was made
in the back of the animals, and a pump was inserted. Animals were sutured and allowed
to recover before being returned to their home cages. Mice were infused with nicotine
or saline for 10 days and on day 11, they were challenged with different nicotine doses
and tested for antinociception (tail-flick and hot-plate tests) and hypothermia.
Calculations for MPE were performed as described previously.
Statistical Analysis
Statistical analysis of all behavioral studies was performed with mixed-factor
ANOVA with post-hoc Tukey’s test when appropriate. P-values of <0.05 were
considered to be statistically significant. For chronic tolerance studies, ED50 (effective
dose 50%) values were calculated with 95% confidence intervals by unweighted leastsquares linear regression as described by Tallarida and Murray (1987). Tests for
parallelism were calculated according to the method of Tallarida and Murray (1987). If
confidence limit values did not overlap, then the shift in the dose-response curve was
considered significant. Potency ratios were also calculated by dividing nicotine ED50
values by saline ED50 values for each age group and pharmacological measure to
determine whether tolerance differences were significant between age groups.
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C. Results
Nicotine’s pharmacological effects after acute injection
Dose-response relationships were established for nicotine in male and female
mice of both ages by measuring antinociception (two tests), hypothermia and
hypomotility at the time of maximal effect (Fig. 10) and ED50s (CL) values were then
determined for each age in different tests (Table 1).
Males
In the tail-flick test, early adolescent male mice displayed decreased sensitivity
as compared to male adult mice (Fig. 10a). ED50 values with confidence limits were 1.7
(1.3-3.6) and 1.0 (0.6-1.2) mg/kg for adolescent and adult age groups, respectively
(Table 1). However, no significant differences between the two age groups were
observed in the hot-plate, hypothermia, and hypomotility tests (Fig. 10b, 10c, 10d). In
addition, all acute responses to nicotine in adult and adolescent mice were blocked by
mecamylamine at 1.0 mg/kg (data not shown). Baseline levels in the tail-flick and hotplate tests were not significantly different between the two ages, respectively (PND 21:
2.9 ± 0.2, 12.5 ± 1.3, PND 70: 2.7 ± 0.3, 13.0 ± 1.8 sec).
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Figure 10. Nicotine’s acute pharmacological effects in adult and adolescent male
mice. Mice from two age groups (PND 21 and PND 70) were injected s.c. with
various acute doses of nicotine and tested in the following responses: (a) tail-flick
test, (b) hot-plate test, (c) hypothermia, and (d) locomotor activity. Each point
represents the mean ± S.E. of 12 mice.

10

61
Females
Females also showed no differences in baseline measures for tail-flick and hotplate tests: (PND 28: 2.5 ± 0.2, 12.2 ± 0.5, PND 70: 2.4 ± 0.2, 13.8 ± 1.0). The hot-plate
and hypothermia measures revealed that early adolescent mice displayed increased
sensitivity as compared to adult mice (Fig. 11b and 11c). In the hot-plate test, ED50
values with confidence limits were 0.4mg/kg (0.3-0.6mg/kg) and 0.9mg/kg (0.81.2mg/kg) for adolescent and adult age groups respectively (Table 1). Likewise, ED50
values in the hypothermia measure were 0.5mg/kg (0.2-0.8mg/kg) and 1.3mg/kg (0.92.0mg/kg) for adolescent and adult mice respectively. In addition, all acute responses to
nicotine in adult and adolescent mice were blocked by mecamylamine at 1.0 mg/kg
(data not shown).
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Figure 11. Nicotine’s acute pharmacological effects in adult and adolescent
female mice. Mice from two age groups (PND 21 and PND 70) were injected s.c.
with various acute doses of nicotine and tested in the following responses: (a) tailflick test, (b) hot-plate test, (c) hypothermia, and (d) locomotor activity. Each
point represents the mean ± S.E. of 12 mice.
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PND 21
Male
1.7 (1.3-3.6)*

PND 70
Male
1 (0.6-1.2)

PND 21
Female
2.3 (0.7-4.5)

PND 70
Female
3 (1.8-5.6)

0.5 (0.4-0.6)

0.5 (0.4-0.6)

0.4 (0.3-0.6)*

0.9 (0.8-1.2)

0.7 (0.5-1.9)

1.1 (0.5-2.2)

0.5 (0.2-0.8)*

1.3 (0.9-2.0)

0.5 (0.15-2)

0.3 (0.1-0.8)

0.4 (0.1-2.4)

0.4(0.1-0.6)

Tail-flick
Hot-plate
Hypothermia
Hypomotility

Table 1: Summary of nicotine potency in young and adult mice after acute
injections. Mice from two age groups (PND 21 and PND 70) were injected s.c. with
various doses of nicotine and tested in the following responses: tail-flick test; hot
plate test; hypothermia; locomotor activity. ED50 values ± confidence limits (± CL)
were calculated from the dose-response curve of the respective treatment and
expressed as mg/kg. Each dose group included 12 animals. * Indicates significant
age differences as compared to adult (CLs do not overlap).
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Development of tolerance to nicotine after chronic exposure
Males
As shown in Fig. 12, tolerance developed to nicotine’s antinociceptive and
hypothermic effects in both adult and adolescent male mice as reflected by the
rightward shift in the dose-response curves. Furthermore, these shifts were significant
as demonstrated by the significant increase (with non-overlapping confidence limits) in
ED50 values after chronic nicotine (Table 2). To determine if the degree of tolerance
was significantly different between the age groups, we calculated potency ratios for
each group (Table 4). Adolescent male mice showed a higher degree of tolerance in the
hot-plate test [potency ratios with confidence limits for adolescent and adults are 2.31
(2.03-2.62) and 1.75 (1.47-1.98)] respectively; however, tolerance to the tail flick and
body temperature developed at the same degree.
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Figure 12. Dose-response curve of nicotine after chronic administration in adult
(PND 70) and adolescent (PND 21) male mice. Animals were chronically infused
with saline or nicotine at 48 mg/kg/day for 10 days via osmotic mini-pump. On
day 11 mice were challenged with nicotine and evaluated in tail flick and hot plate
analgesia and hypothermia. Adolescent mice are shown in graphs (a), (b), and (c)
and adult mice are shown in graphs (d), (e), and (f). Each point represents the
mean ± S.E. of 12 mice.
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Adolescent
Saline
Tail-Flick Test 1.8 (1.6-1.9)

Adult
Saline

Adult
Nicotine

0.8 (0.7-0.9)

1.8 (1.5-2.0)

*

0.9 (0.8-1.0)

1.5 (1.3-1.7)

*

0.9 (0.8-1.1)

1.4 (1.3-1.6)

Adolescent
Nicotine

3.7 (3.5-3.8)

*

Hot-Plate Test

1.5 (1.1-1.7)

3.8 (3.67-4.0)

Hypothermia

1.1 (0.8-1.5)

2.3 (1.8-3.0)

Table 2. ED50 values of tolerance studies after chronic administration of nicotine
in adult and adolescent male mice. Mice were chronically infused with nicotine at
48 mg/kg/day for 10 days via osmotic mini-pump. On day 11 mice were challenged
with nicotine and evaluated in three tests: tail-flick, hot-plate, and hypothermia.
ED50 values ± Confidence limits (± CL) were calculated from the dose-response
curve of the respective treatment and expressed as mg/kg. Each dose group
included 12 animals. *Indicates a significant difference as compared to the saline
control (CLs do not overlap).

*
*
*
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Females
As shown in Fig. 13, tolerance also developed to nicotine’s antinociceptive
effects in female mice of both ages. These shifts were statistically significant as
demonstrated by the increase in ED50 values after chronic nicotine (Table 3), which
have non-overlapping confidence limits. Table 4 summarizes the potency ratios which
are indicative of whether tolerance levels were significantly different between the early
adolescents and adults. Indeed, female adolescent mice showed a lower degree of
tolerance in the hypothermia measure [potency ratios with confidence limits for
adolescent and adults are 1.35 (1.10-1.69) and 1.93 (1.77-2.23) respectively].
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Figure 13. Dose-response curve of nicotine after chronic administration in adult
(PND 70) and adolescent (PND 21) female mice. Animals were chronically infused
with saline or nicotine at 48 mg/kg/day for 10 days via osmotic mini-pump. On
day 11 mice were challenged with nicotine and evaluated in tail flick and hot plate
analgesia and hypothermia. Adolescent mice are shown in graphs (a), (b), and (c)
and adult mice are shown in graphs (d), (e), and (f). Each point represents the
mean ± S.E. of 12 mice.
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Tail-Flick Test
Hot-Plate Test
Hypothermia

Adolescent
Saline

Adolescent
Nicotine

Adult
Saline

Adult
Nicotine

1.9 (1.7-2.1)

3.2 (2.4-4.2)*

2.8 (2.7-3.0)

4.3 (3.9-4.8)*

1.7 (1.4-2.0)

3.0 (2.4-3.7)*

2.6 (2.4-2.8)

3.8 (3.5-4.8)*

0.8 (0.6-1.1)

1.0 (0.9-1.2)

1.4 (1.1-1.7)

3.4 (3.1-3.7)*

Table 3. ED50 values of tolerance studies in female mice. Female ICR mice were
chronically infused with nicotine at 48 mg/kg/day for 10 days via osmotic minipump. On day 11 mice were challenged with nicotine and evaluated in three tests:
tail-flick, hot-plate, and hypothermia. ED50 values ± Confidence limits (± CL)
were calculated from the dose-response curve of the respective treatment and
expressed as mg/kg. Each dose group included 12 animals. *Indicates a significant
difference as compared to the saline control (CLs do not overlap).
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Adolescent
Males

Adult
Males

Adolescent
Females

Adult
Females

Tail-Flick Test

1.9 (1.7-2.1)

2.0 (1.7-2.3)

1.5 (1.2-1.9)

1.4 (1.3-1.6)

Hot-Plate Test

2.3 (2.0-2.6)*

1.7 (1.4-1.9)

1.7 (1.3-2.2)

1.4 (1.3-1.6)

Hypothermia

2.2 (1.2-3.6)

1.6 (1.3-1.9)

1.3 (1.1-1.6)*

1.9 (1.7-2.2)

Table 4. Potency ratios for tolerance studies in male and female ICR mice.
Potency ratios with confidence intervals are given for each group. * Indicates a
significant difference between adolescent and adult groups in a particular test
(confidence limits do not overlap).
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D. Discussion
Acute sensitivity and tolerance to nicotine were examined in this chapter as
possible underlying mechanisms of age-specific behavioral differences in components
of nicotine dependence. Following acute treatment with nicotine, adolescent male mice
displayed a nicotine-induced antinociception compared to adults in the tail-flick test.
This finding suggests that, in male adolescents, predisposition to maintain use of
nicotine might be due to the lessening of aversive effects due to decreased sensitivity to
the drug. However, since there was only a decrease in the tail-flick test while the other
measures showed no changes between the two age groups, it does not appear that acute
sensitivity to nicotine is a major contributing factor.
The data from our tolerance study show that adolescent male mice produce a
greater degree of tolerance to nicotine-induced antinociception as compared to adult
mice in the hot plate test. The tolerance level is an important factor in evaluating
nicotine dependence. The higher tolerance seen in male adolescents suggests that this
age group would have to smoke more to achieve the same level of effect as an adult
leading to a greater intake of nicotine in adolescence and an increase in the likelihood of
becoming dependent. However, again only one measure of tolerance was significantly
different between the two age groups in males suggesting a minor role for this
mechanism.
Similarly in females, initial sensitivity to acute nicotine and tolerance to nicotine
did not appear to play a large role in the differences in nicotine dependence between
adults and adolescents. Adolescent female mice displayed an increased sensitivity to
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acute nicotine treatment as compared to adults in the analgesic and hypothermia tests.
This factor may contribute to the difficulty in quitting, but probably does not contribute
greatly since not all measures were indicative of increased sensitivity. The data from
our tolerance study show that female adolescent mice produce a lower degree of
tolerance to nicotine-induced hypothermia as compared to adult mice, but no
differences were observed in antinociceptive measures. Since we only saw differences
in potency in one measure, it is also unlikely that this factor is a substantial contributor.
Taken together, these data suggest that differences in acute sensitivity and
tolerance to nicotine only play a minor role in age-related differences in nicotine
dependence. In addition to behavioral mechanisms, it is also important to consider
variations in molecular and cellular mechanisms in order to understand drug
dependence. In Chapter 5, we will consider mechanisms that examine receptor number
and function, as well as differences in downstream signaling that may contribute to
elevated levels of nicotine dependence in adolescents. Although differences in female
mice were noted throughout in vivo studies, we have chosen to investigate the male sex
for the remainder of the studies. We felt that it was beyond the scope of the project to
address both sexes and have focused our attention on fully characterizing the male sex.

AN EXAMINATION OF THE PHASE OF ADOLESCENT NICOTINE
EXPOSURE ON NICOTINE REWARD AND WITHDRAWAL IN MALES

A. Introduction
Chapters 2 and 3 demonstrate that early adolescent mice show different levels of
nicotine dependence as compared to adult mice. However, it is important to know
whether this specific phase of adolescence is unique or if age-related differences are
also found during subsequent adolescent periods. Indeed, early adolescence has been
implicated as the most critical period of adolescent development. Belluzzi et al. (2004)
have shown that rats exposed to nicotine during early adolescence (P28) displayed
conditioned place preference, while older adolescents and adults fail to do so.
Moreover, Vastola et al. (2002) also found that only rats conditioned during early
adolescence showed preference to nicotine. Behavioral studies in nicotine withdrawal
have also focused on early adolescence (O’Dell et al. 2006; Shram et al. 2006) and have
reached similar conclusions regarding age-specific differences. However, few studies
have investigated other phases of adolescence to examine their susceptibility to
dependence behaviors. One study reported that early adolescent mice demonstrated a
preference for oral nicotine, while middle and late adolescents showed no preference
(Adriani et al. 2002) suggesting the uniqueness of this phase. The aim of this chapter
was to examine all three phases of adolescence in the CPP model and to examine the
late adolescent phase in regards to signs of nicotine withdrawal. As a reminder, these
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studies were only conducted in male subjects as studying these effects in females is
beyond the scope of this project.
B. Methods
Nicotine-induced conditioned place preference studies
The same general procedure as previously described in Chapter 2 was used for
this experiment. In addition to another set of early adolescent (PND 21) and adult
(PND 70) mice, middle (PND 35) and late (PND 49) adolescent mice were also tested
for nicotine-induced rewarding effects.
Precipitated nicotine withdrawal studies
Withdrawal testing was performed exactly as previously described in Chapter 2
using the osmotic mini-pump model. Mice were PND 49 upon mini-pump implantation
and were tested 8 days later for mecamylamine-induced withdrawal signs.
Statistical Analysis
Statistical analysis of all behavioral studies was performed with mixed-factor
ANOVA with post-hoc Tukey’s test when appropriate. P-values of <0.05 were
considered to be statistically significant.
C. Results
Effect of Adolescent Phase on Nicotine-Induced Conditioned Place Preference
Nicotine-induced CPP in all stages of adolescence is shown in Figure 14.
Consistent with previous results in the adult, neither middle nor late adolescent mice
displayed an enhanced CPP in response to low doses of nicotine. A significant
preference was only established at a dose of 0.5 mg/kg for these three age groups. In

75
contrast, early adolescent mice demonstrated a clear preference for both 0.05 and 0.1
mg/kg nicotine which are inactive doses in older animals; thus suggesting an increased
sensitivity to the rewarding effects of nicotine during this stage of development. These
data support the hypothesis that early adolescence is the most critical stage for nicotineinduced rewarding effects.
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Figure 14. Age-dependent nicotine-induced conditioned place preference in male
mice. Adult (PND 70), late adolescent (PND 49), middle adolescent (PND 35) and
early adolescent (PND 21) were conditioned s.c. with various doses of either saline
or nicotine using the CPP paradigm. Positive scores indicate a preference for
nicotine while negative scores are indicative of aversion to the drug. Scores at or
near zero indicate neither preference nor aversion. Each point represents the mean
± SEM of 8-9 mice. *p<0.05 from saline group.
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Effect of Adolescent Phase on Nicotine Withdrawal
As with the conditioned place preference model, we also investigated how the
stage of adolescence affected levels of nicotine withdrawal. We examined this question
by precipitating nicotine withdrawal in late adolescent male mice after chronic
administration of the drug. In order to easily compare adult, early adolescent and late
adolescent data, we have graphed our results together as seen in Figure 15. Control
groups were included in this experiment; however, no significant differences were noted
so data is only shown in table format (Table 5) in order to simplify the graphs.
As previously stated, early adolescent mice displayed lower withdrawal signs as
compared with adult mice. Particularly, somatic signs and hyperactivity measures were
found to be significantly attenuated (Fig. 15a, 15d). Furthermore, there was no
evidence of withdrawal behavior in the elevated plus maze (Fig. 15b) or in hyperalgesia
(Fig. 15c) testing for early adolescent mice. On the other hand, late adolescent mice
displayed withdrawal behavior in all four measures and there were no significant
differences noted between adult and late adolescent withdrawal intensity. This suggests
that early adolescents, but not late adolescents, have a decreased vulnerability to
nicotine’s aversive effects.
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Adult
Sal MP/Sal Inj

Adult
Nic MP/Sal Inj

Early Adolescent
Sal MP/Sal Inj

Early Adolescent
Nic MP/Sal Inj

Late Adolescent
Sal MP/Sal Inj

Late Adolescent
Nic MP/Sal Inj

4±1

3±1

3±0

2±0

2±2

3±1

28.5 ± 1.4

26.8 ± 3.0

33.6 ± 2.5

29.9 ± 1.8

30.7 ± 3.3

32.6 ± 2.0

HP

9 ± 1.1

10.6 ± 0.8

8.5 ± 0.3

8.3 ± 0.9

8.6 ± 0.7

LA

1064 ± 98

968 ± 58

988 ± 65

1102 ± 54

1036 ± 39

SS
EPM

7.5 ± 0.3
1002 ± 42

Table 5: Summary of control data for precipitated nicotine withdrawal
experiments in adult (PND 70), early adolescent (PND 21), and late adolescent
(PND 49) male mice. Mice were chronically infused with nicotine at 48 mg/kg/day
or saline for 7 days. On day 8, mice were injected with 2.0 mg/kg of
mecamylamine or saline s.c. to precipitate withdrawal and evaluated in four tests:
somatic signs, elevated plus maze, hot plate analgesic test, and locomotor activity.
MP=mini-pump; Inj=injection
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Figure 15. Mecamylamine-precipitated withdrawal in adult (PND 70), early
adolescent (PND 21), and late adolescent (PND 49) male mice. Mice were
chronically infused with nicotine at 48 mg/kg/day or saline for 7 days. On day 8,
mice were injected with 2.0 mg/kg of mecamylamine or saline s.c. to precipitate
withdrawal and evaluated in four tests: (a) somatic signs, (b) elevated plus maze,
(c) hot plate analgesic test, and (d) locomotor activity. (n=12/group)
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D. Discussion
Early adolescence has been identified as a critical period of both physical and
neuronal development. Specifically, a vast amount of pruning and synapse loss has
been reported. It has been estimated that as many of half of the average number of
synapses are lost during adolescence (Rakic et al. 1994). These changes may
contribute to differences in behavioral responses over certain periods of development.
Only a limited number of studies have investigated nicotine’s behavioral effects
throughout all phases of adolescence. It is unclear if each phase is important in the
development of drug dependence or if this susceptibility is limited to early adolescence.
Data from our studies demonstrate that early adolescence is unique in both reward and
withdrawal models.
Only early adolescent mice demonstrated a significant preference for low doses
(0.05 and 0.1 mg/kg) of nicotine in the CPP model. This indicates that minimal
exposure to nicotine may be able to elicit rewarding effects at this age due to enhanced
sensitivity. In contrast, older adolescents and adults only displayed preference at a
higher dose of nicotine: 0.5 mg/kg. Our data are in agreement with that of a previous
study which found that only early adolescent mice displayed preference for oral nicotine
(Adriani et al. 2002). In the withdrawal model, early adolescent mice demonstrated a
significant attenuation of both physical and affective signs of withdrawal as compared
to adults. On the other hand, late adolescents showed no differences from adults in any
of the four withdrawal measures indicating that the intensity of withdrawal is similar in
these two age groups.
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Taken together, these data support the hypothesis that, in males, early
adolescence represents a unique phase of development in which rewarding effects are
enhanced and withdrawal signs are attenuated. This implies that humans may be more
vulnerable to nicotine dependence if exposure begins at an early age. These findings
stress the critical nature of early prevention messages and intervention strategies that
combat teenage smoking. Indeed, studies have found that the commencement of
smoking at a young age is thought to increase addiction, decrease the probability of
successful cessation (Colby et al. 2000; Kandel and Chen 2000), and correlate with a
higher number of cigarettes smoked per day (Taoli and Wynder 1991). It is important
that we increase our understanding of the mechanisms behind this enhanced
vulnerability so that smoking cessation therapies and treatments which are age
appropriate can be properly developed. For these reasons, molecular studies will
continue to focus on the early adolescent phase due to its apparent significance in the
initiation of smoking.

MOLECULAR MECHANISMS INVOLVED IN NICOTINE DEPENDENCE

A. Introduction
Early adolescent and adult mice display different responses in models of
nicotine reward and withdrawal. It is likely that functional properties, distribution, and
number of nAChRs could contribute to these differences. Additionally, alterations in
receptor number and function may lead to changes in downstream signaling which will
affect pharmacological responses to nicotine. The goal of these experiments was to
investigate these possibilities in order to further our understanding of early adolescent
vulnerability to nicotine dependence.
Recently, it was reported that the quantity and distribution of nAChRs changes
as development progresses. Specifically, Azam et al. (2007) found that α5, α6, and α7
mRNAs reach peak levels in early adolescence then decrease to lower adult levels. In
addition, the authors reported regional differences in expression of α5, α6, and β3
mRNAs with elevated levels in the substantia nigra as compared to the ventral
tegmental area. Furthermore, adolescent nicotine exposure appears to have important
molecular consequences. One study examined the effects of acute nicotine exposure on
several early response genes which are thought to be involved in synaptic plasticity and
addiction. The study found that rats which were exposed to nicotine during adolescence
showed an induction of arc mRNA in the PFC. Other genes, such as c-fos, were also
upregulated by nicotine independent of age (Schochet et al. 2005). Finally, research by
Levin et al. (2007) correlated an increase in nicotine i.v. self-administration in
adolescent rats with significantly greater high affinity nicotinic receptor (α4β2) binding
in the midbrain and the striatum as compared to adults. Taken together, these data
suggest that adolescent nicotine exposure has important consequences on brain
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maturation and development. Furthermore, nicotine may be causing alterations in
receptor subtypes and function which will have critical downstream effects that may
lead to increases in addiction vulnerability. Although some studies have examined the
effect of nicotine on downstream signaling in adolescent rodents, only limited studies
have directly compared age-related differences in distribution and expression of
nAChRs before and after nicotine exposure.
Our approach in investigating these mechanisms involved beginning at the
major target of nicotine, the nicotinic acetylcholine receptor. Rubidium efflux is a wellknown and well-established model which is used to assess nAChR function. Many of
the behavioral responses which have been examined in these studies are mediated by
the α4β2* subtype (the major subtype measured in this assay) which is why we began
with this approach. In addition to rubidium efflux, we performed nAChR binding
studies to investigate basal differences in receptor levels between adults and early
adolescents. Although this method is not a direct measure of receptor function, it has an
advantage over assessing mRNA levels in that it directly measures protein levels.
Finally, our dopamine release assay was performed in order to investigate particularly
important effects downstream of the receptor activation. Dopamine is known to be an
important neurotransmitter which is involved in the mesolimbic reward pathway that
contributes to the addictive nature of nicotine. Together these studies aim to enhance
the understanding of the molecular and cellular pathways of nicotine dependence.
B. Methods
Rubidium Efflux Studies
Unless otherwise noted, all reagents were purchased from Sigma Chemical Co.,
St. Louis, MO. Mice were rapidly decapitated and four brain regions were dissected for
use in the assay (striatum, frontal cortex, hippocampus, and thalamus). Brain regions
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were pooled from several mice if needed. In this experiment, we used striatum from 5
mice, cortex from 2 mice, hippocampus from 3 mice, and thalamus from 1 mouse.
Synaptosomes were prepared according to Marks et al. (1993a, 1993b). Briefly,
synaptosomes were prepared by hand homogenizing tissue in cold 0.32M sucrose
(1ml/g tissue). After centrifugation, pellets were resuspended in cold load buffer
(140mM NaCl, 1.5mM KCl, 2mM CaCl2, 1mM MgSO4, 25mM HEPES hemisodium
salt, 20mM glucose, pH 7.4). A 25-µl aliquot of the synaptosome suspension was
incubated for 40 min with 10µl load buffer containing approximately 4µCi 86RbCl
(Perkin Elmer Life Sciences, Boston, MA). After the synaptosomes were filtered onto
glass fiber filters under gentle vacuum, the filters were rinsed with 0.5ml of load buffer
and placed on the perfusion apparatus for washing with perfusion buffer (135mM NaCl,
5mM CsCl, 1mM MgSO4, 2mM CaCl2, 1.5mM KCl, 1g/l bovine serum albumin, 50nM
tetrodotoxin, 25mM HEPES hemisodium salt, pH 7.4) for six min. The filter containing
synaptosomes was subsequently perfused continuously. Filters were stimulated for one
minute with various concentrations of nicotine prepared in perfusion buffer followed by
a three-minute wash with perfusion buffer alone. Twelve-second fractions were
collected in 12 x 75-mm test tubes beginning six min into the perfusion. Samples were
counted for one minute each in a Wallac Wizard 3'' 1480 Automatic Gamma Counter;
(PerkinElmer, Shelton, CT). The magnitude of 86Rb+ efflux response was calculated
based on the increase in counts above baseline after stimulation of the tissue with
nicotine. Data were calculated as fractional release (cpm/total cpm loaded on filter) for
each fraction collected. The baseline was calculated for each mouse by fitting to an
exponential equation the fractional release in fractions immediately preceding and
following the peak. The area under the curve was calculated for each mouse using this
mathematically derived baseline and the fractional release values in the peak.
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Nicotinic Receptor Binding
Materials
(±)-[3H]Epibatidine (48 Ci/mmol) and L-[3H]nicotine (78 Ci/mmol), were
purchased from Du Pont NEN (Boston, MA). alpha -[125I]Bungarotoxin (Initial
specific activity = 220 Ci/mmol) plastic tritium standards and Hyperfilm-3H were
purchased from Amersham (Mount Prospect, IL). NaCl, KCl, MgSO4, CaCl2, gelatin,
chromium aluminum sulfate, cytisine, acetylcholine and diisopropyfluorophosphate
were obtained from Sigma Chemical Co. (St. Louis, MO). Methylcarbachol chloride,
(+)-epibatidine tartrate, and (-)-epibatidine tartrate were obtained from RBI (South
Natick, MA). Nicotine bitartrate was a product of BDH Chemicals (Poole, England).
Glass fiber filters Type A/E were obtained from Gelman Sciences (Ann Arbor, MI) and
Type GB from MFS (Dublin, CA). Budget Solve scintillation fluid was obtained from
RPI (Arlington Heights, IL).
Tissue preparation
Each mouse was killed by cervical dislocation; the brain was removed from the
skull and placed on an ice-cold platform. The following 4 brain regions were dissected:
nucleus accumbens (NAc), ventral tegmental area (VTA), hippocampus (HIP), and
prefrontal cortex (PFC). Samples were homogenized in ice-cold hypotonic buffer
(NaCl, 14.4 mM; KCl, 0.2 mM; CaCl2, 0.2 mM; MgSO4, 0.1 mM, HEPES, 2.0 mM;
pH = 7.5) using a glass-Teflon tissue grinder. The particulate fraction was obtained by
centrifugation at 20,000 × g for 20 min in a Sorvall RC-2B centrifuge. The pellet was
resuspended in fresh homogenization buffer, incubated at 37°C for 10 min, and
harvested by centrifugation. Each sample was washed twice more by resuspension and
centrifugation and stored as a pellet under homogenization buffer at -70°C until use.
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[3H]nicotine binding
The binding of [3H]nicotine was measured using a modification of the method of
Marks et al. (1986). Samples (50-200 µg, depending on brain region) were incubated in
96-well polystyrene plates with 20 nM [3H]nicotine at 22°C for 30 min in 100 µl of
binding buffer (NaCl, 144 mM; KCl, 1.5 mM, CaCl2, 2 mM; MgSO4, 1 mM; HEPES,
20 mM; pH = 7.5). The binding reaction was terminated by filtration of the samples
onto glass fiber filters (MFS GB top, Gelman A/E bottom) that had been soaked in
binding buffer containing 0.5% polyethylenimine using an Inotech Cell Harvester
(Inotech, East Lansing, MI). Samples were subsequently washed six times with ice-cold
binding buffer. Nonspecific binding was determined by including 10 µM L-nicotine in
the assay.
alpha -[125I]bungarotoxin binding
The binding of alpha -[125I]bungarotoxin was measured using a modification of
the method of Marks et al. (1986). The binding reaction was similar to that used for
[3H]nicotine with the following changes: incubation time was 5 hr, samples contained 1
nM alpha -[125I]bungarotoxin instead of [3H]nicotine and the binding buffer also
included .025% bovine serum albumin. Blanks were determined by including 1 mM Lnicotine in the assay.
[3H]epibatidine binding
The binding of [3H]epibatidine was measured in a method analogous to that of
[3H]nicotine with the following changes: incubations were in 1-ml polypropylene tubes
in a 96-well format, incubation volume was 500 µl, and [3H]epibatidine rather than
[3H]nicotine was used. Nonspecific binding was determined by including 100 µM Lnicotine in the assay. Nonspecific binding at all concentrations of [3H]epibatidine was
less than twice background (40 dpm). The following experiments were conducted:
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construction of curves for inhibition of [3H]epibatidine binding in olfactory bulbs by
cytisine, nicotine, acetylcholine (using tissue treated with 10 µM
diisopropylflourophosphate during the tissue preparation), methylcarbachol, (+)epibatidine and (-)-epibatidine (preliminary experiments indicated that inhibition in
olfactory bulbs deviated markedly from that expected for a single site); construction of
curves for inhibition of [3H]epibatidine binding in 4 brain regions by cytisine; and
measurement of the concentration dependence of [3H]epibatidine binding in 4 brain
regions. The concentration of [3H]epibatidine used for inhibition curves was about 400
pM (approximately 20 x Kd). This concentration was chosen to maintain ligand binding
to the tissue to less than 5% of the total. An incubation time of 60 min was used for
these experiments (equilibrium was reached in 20-30 min). For saturation curves, eight
[3H]epibatidine concentrations between 6 and 800 pM were used. Incubation time for
these experiments was 2 hr (equilibrium was reached by 60 min for all concentrations).
In these experiments a significant fraction of the [3H]epibatidine was bound to the
tissue, especially at lower ligand concentrations. Free [3H]epibatidine concentration was
estimated by correcting for the amount of ligand bound to the tissue at each
concentration for every brain region.
Protein
Protein was measured using the method of Lowry et al. (1951) with bovine
serum albumin as the standard.
Calculations
Results for saturation binding experiments were calculated using the Hill
equation: B = Bmax*Ln/(Ln + Kdn), where B is the binding at free ligand concentration, L,
Bmax is the maximum number of binding sites, Kd is the equilibrium dissociation
constant, and n is the Hill coefficient. Values of Bmax, Kd and n were calculated using
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the nonlinear least squares algorithm in Sigma Plot 5 (Jandel Scientific, San Rafael,
CA). Results for inhibition of epibatidine binding were calculated using the formulas
for either one or two binding sites: B = B0/(1+(I/IC50)) or B = B1/(1+(I/IC501))

+ B2/(1+(I/IC50-2)), respectively, where B is ligand bound at inhibitor concentration,

I, B0 is the binding in the absence of inhibitor, and B1 and B2 are the binding to two sites
sensitive to inhibition with IC50-1 and IC50-2. Assuming competitive inhibition: IC50 = Ki
x (1 + L/Kd). Results were also calculated using the Hill equation.
Dopamine Release Assay
Materials
7,8-[3H]Dopamine was obtained from PerkinElmer Life and Analytical Sciences
(Boston, MA) (specific activity, 40–60 Ci/mmol).
Membrane Preparation
Adult and adolescent male mice were sacrificed by cervical dislocation. The
brain was removed from the skull and was immediately placed on ice for dissection.
Striatum was isolated and removed from the brain. Tissue was homogenized (16-20
strokes by hand) in 0.5 ml of 0.32 M sucrose buffered with 5 mM HEPES, pH 7.5.
Synaptosomal pellets were then prepared by centrifugation at 1000g for 10 min,
followed by centrifugation of the resulting supernatant at 12,000g for 20 min. The
pellets were resuspended in perfusion buffer (128 mM NaCl, 2.4 mM KCl, 3.2 mM
CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, pH 7.5, 10 mM glucose, 1
mM ascorbic acid, and 0.01mM pargyline. The perfusion procedure has been described
previously (Grady et al., 1997). Briefly, synaptosomes were incubated at 37°C in
perfusion buffer for 10 min before addition of 100 nM [3H]dopamine (1 µCi for every
0.2 ml of synaptosomes). Aliquots of synaptosomes (80 µl) were distributed onto filters
and perfused at 0.6 ml/min for 10 min before fractions were collected. [3H]dopamine
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were added at the same time during the last 5 min of the uptake procedure. Atropine (1
µM) was added to the perfusion buffer to inhibit muscarinic receptors. Various
concentrations of nicotine were used to stimulate dopamine release. Fractions were
collected every 30s, and radioactivity was determined by scintillation counting (1600TR
liquid scintillation spectrometer; Packard Instrument Co.) after addition of EconoSafe
(Sigma/RBI, Mt. Prospect, IL).
Statistical Analysis
Nicotine stimulated 86Rb+ efflux was analyzed with a two-way analysis of
variance (ANOVA) and a one-way ANOVA as a function of age. These were followed
by Tukey post hoc tests. EC50 (effective concentration 50%) were calculated by
unweighted least-squares linear regression as described by Tallarida and Murray (1987).
A P value of <0.05 was considered statistically significant. nAChR binding studies
were analyzed using two-way ANOVAs with appropriate post-hoc tests when
necessary. EC50s were calculated for dopamine release assay curves. Individual
concentrations were also analyzed with two-way ANOVAs with Tukey post-hoc tests
when appropriate.
C. Results
Rubidium Efflux Studies
Dose-response curves for nicotine-stimulated synaptosomes were generated for
both adults and adolescents in four brain regions: striatum, cortex, hippocampus, and
thalamus (Fig. 16; data represented by a Michaelis-Menten curve fit where
y=m1*x/(m2+x)). Synaptosomes were responsive to nicotine stimulation in a dosedependent manner until approximately 100µM of nicotine at which point the response
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reached its peak. Adolescent mice displayed greater nAChR functionality with larger
differences at lower concentrations of nicotine. The difference is also evident by the
shift to the left of nicotine dose-response curves in adolescent compared to that of adult
mice (Fig.16). Estimated EC50 values for both age groups are as follows in adolescents:
striatum=0.53µM; cortex=0.79µM; hippocampus=0.96µM; and thalamus=0.53µM.
EC50 values for adults were: striatum=1.61µM; cortex=10.77µM;
hippocampus=3.13µM; and thalamus=3.93µM. We have coupled this analysis with the
total AUC which is a more comprehensive measure of nAChR functionality. As shown
in Fig. 17, adolescent mice displayed significantly higher nicotinic receptor
functionality than adults in all four brain regions tested.
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Figure 16. Dose response curves from the striatum, cortex, hippocampus, and
thalamus regions of adult (PND 75) and adolescent (PND 28) male mice.
Synaptosomes from brain tissue were stimulated with various doses of nicotine for
one minute to generate dose-response curves. Area under the curve is shown on
the y-axis and nicotine dose is shown on the x-axis. Data are represented by a
Michaelis-Menten curve fit where y=m1*x/(m2+x). In the striatum, R values =0.97
(adolescents) and 0.87 (adults). In the cortex, R values = 0.99 (adolescents) and
0.81 (adults). Adolescent mice (dashed line) displayed higher nAChR functionality
as compared to adult mice (solid line). Results are expressed as mean AUC ± S.E.
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Figure 17. Total area under the curve for all doses of nicotine in the rubidium
efflux assay in four brain regions. Results are expressed as mean AUC ± S.E.
* p<0.05 from adult mice.
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Nicotinic Receptor Binding Studies
Results from the nicotinic receptor binding studies are shown in Figure 18.
Binding techniques quantified total nAChRs (a), cytisine sensitive α4β2* nAChRs (b),
α-conotoxin-MII sensitive α6-containing nAChRs (c), and α-bungarotoxin sensitive α7
nAChRs (d) using various pharmacological tools. In the α4β2* and the total nAChR
binding studies, a trend for increased nAChR binding in the adolescent mice was
observed; however no significant differences were found in total nAChR binding or for
a particular nAChR subtype.
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Figure 18. Nicotinic acetylcholine receptor binding assays were performed on
adult (PND 75) and adolescent (PND 28) ICR mice. Various pharmacological tools
were used to assess the following nAChR subtypes: (a) total nAChR binding; (b)
cytisine-sensitive binding (α4β2); (c) alpha-conotoxin (α6); and (d) alphabungarotoxin (α7). Results are expressed as receptor density normalized to
protein. Bars represent the mean ± S.E. of 6-8 mice.
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Dopamine Release Assay
Figure 19 shows the results from the dopamine release assay which examined
levels of dopamine release from the striatum in adult and adolescent mice. Doseresponse curves were calculated for both age groups over a range of nicotine doses.
The graph shows that there was a trend for an increased dopamine release from
adolescent synaptosomes. However, this increase was not significant when all data was
compiled together as total area under the curve.
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Figure 19. Dopamine release from striatal synaptosomes in adult (PND 75) and
adolescent (PND 28) mice. Striatal synaptosomes were stimulated with various
concentrations of nicotine to generate a dose-response curve. Each point
represents the mean ± S.E. of 6-8 mice. Total area under the curve is also
presented in the graph to the right with adults represented by the solid black bar
and adolescents represented by the hatched bar. * p<.05 from same concentration
in adult.
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D. Discussion
The data in this chapter show that there is a clear and significant increase in
nAChR functional response to nicotine in adolescent mice as compared to adults
(Figures 16 and 17). This increase is consistent in four important brain regions
(striatum, cortex, hippocampus, and thalamus) which contribute to nicotine addiction
and dependence. Our data also agree with recent findings in the rat (Britton et al. 2007)
where nicotine-stimulated rubidium efflux peaked during adolescence (~PND 35). This
increased functionality of adolescent receptors could be playing a role in the behavioral
observations seen in the conditioned place preference and withdrawal models. Our
results support the observation of an enhanced preference in the CPP model in that
increased nAChR function would translate into increased responsiveness to the
rewarding effects of nicotine. In contrast, correlations to the results from our
withdrawal studies are not as clear. There are differences between the two studies
which may account for differences in the results. Rubidium efflux studies were
conducted in naïve mice while withdrawal studies were conducted after chronic
exposure to nicotine. It is possible that nAChRs may be regulated differently after
chronic drug treatment which would contribute to inconsistencies.
These results could imply several other possibilities for age-related differences
in behavioral models. It is logical to consider that increased functional response may be
due an increase in basal levels of nAChRs in adolescent as compared to adult animals.
For this reason, we investigated nAChR binding in the brain in these two ages. We
found no significant differences in receptor binding in our study. Furthermore, specific
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receptor subtypes were also evaluated and still no differences were observed (Figure
18). In contrast to our findings, Azam et al. (2007) reported that levels of α5, α6, and
α7 mRNA were higher during the adolescent period. However, mRNA data must be
interpreted with caution in that differences in mRNA do not necessarily reflect a similar
change in receptor protein expression. Another possibility is that differences in receptor
stoichiometry (i.e. (α4)2(β2)3 vs. α4α5β2, etc) are not detectable by binding methods.
Since neuronal pathways are still developing in young animals, it is also
possible that the adaptations in the brain during development cause the levels of
dependence to change over time as well. For example, the dopaminergic system is
under great development during adolescence and may account for behavioral
observations. However, results from our dopamine release studies did not find
significant differences between the two age groups in the mouse (Figure 19). On the
other hand, Azam et al. (2007) reported that nicotine-stimulated dopamine release was
significantly higher during the early adolescent period in the male rat. Furthermore,
previous work has demonstrated that dopamine release is attenuated in the adult rat
during withdrawal (DiChiara 2000; Hildebrand et al. 1998). Therefore, it is possible
that adolescents do not experience this same decrease in dopamine thus lowering
withdrawal symptoms and aversive effects. The study by Azam et al. (2007) was
different from our study in that they were comparing nicotine-evoked dopamine release
in animals at even younger ages (PND 7 and PND 14); whereas our study used PND 2428 mice. In addition, no comparisons to adult rodents are given in this report. As
previously mentioned, our assays which used a crude preparation of synaptosomes may
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not ensure complete precision. For example, techniques such as microdialysis may be
more accurate in that it preserves the neuronal connections of an intact neuron. It is
possible that more sensitive assays may be required to denote differences between the
age groups.
An alternative explanation for the behavioral responses which we have observed
may be linked to other receptor types which are known to be involved in nicotine
dependence. For example, glutamatergic receptors have been shown to play a role in
nicotinic effects as well. Research has shown that administration of mGlu2/3 agonists
decreased nicotine, but not food self-administration in rats (Liechti et al. 2007).
Another study showed that nicotine exposure during adolescence dose-dependently
down-regulated GluR2/3 subunits in the striatum and hippocampus while nicotine
exposure in adults did not have this effect (Adriani et al. 2004). This same study also
showed changes in NMDA NR2A/B subunits regardless of the time of exposure
suggesting the involvement of NMDA receptors in certain aspects of nicotine
dependence. These findings suggest that other receptors may also be involved and
should be further examined.

“BEHAVIORAL PLASTICITY”: THE EFFECTS OF ADOLESCENT
NICOTINE EXPOSURE ON NICOTINE DEPENDENCE
A. Introduction
Overall, studies conducted to date suggest that the rewarding and reinforcing
effects of nicotine are enhanced in adolescent versus adult rodents and that early
adolescence may represent a period of heightened vulnerability. Data discussed in
Chapter 2 indicate that in male adolescent mice, there is an increase in sensitivity to
nicotine reward as well as attenuation in withdrawal signs as compared to adults. While
it is clear that there are substantial behavioral age differences in nicotine dependence, it
is still uncertain what type of long-lasting effects adolescent nicotine exposure has on
lifetime nicotine dependence. Human studies have sought to examine this question
since statistics support the concept that those who begin smoking at an early age are
more likely to continue this pattern of behavior. Indeed, over 90% of adult smokers
report their first use of tobacco prior to age 18 (Chassin et al. 1990). The
commencement of smoking at a young age is thought to increase addiction, decrease the
probability of successful cessation (Colby et al. 2000; Kandel and Chen 2000), and
correlate with a higher number of cigarettes smoked per day (Taoli and Wynder 1991).
Since more than 6,000 teenagers begin smoking every day (American Lung Association
Statistics 2002) this is a critical problem which needs to be investigated. Human studies
are limited in that they are unable to discern biological factors since many social,
psychological, and emotional factors may also play an important role. For this reason,
animal models are useful in that they have a biological emphasis.
100
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The goal of this study was to conduct a thorough investigation of the effects of
adolescent nicotine exposure on both nicotine reward and withdrawal in adulthood.
Specifically, dose and duration of exposure were examined to determine how these two
factors contribute to the induction of persistent behavioral changes. In addition to
nicotine reward and withdrawal, locomotor function was measured following adolescent
nicotine exposure. Finally, we investigated the correlation of adolescent nicotine
exposure with measures of nAChR function using the rubidium efflux assay in order to
assess whether early exposure had long-lasting effects at the receptor level. We
hypothesized that chronic exposure to nicotine during early adolescence would have
long-lasting effects on behavior in adulthood.
B. Methods
Drugs
(-)-Nicotine bitartrate and mecamylamine hydrochloride were purchased from
Sigma Chemical Company (Milwaukee, WI). All doses are expressed as free base.
Conditioned Place Preference Studies
Mice received nicotine for various durations during early adolescence (PND 2131), late adolescence (PND 49-59) or adulthood (PND 70-80). Table 6 fully describes
the various experimental groups and the time course of this experiment. Briefly, there
were three durations of nicotine exposure: acute, intermittent, and frequent. Two doses
of nicotine (0.1 and 0.5 mg/kg) or saline were administered s.c. twice daily with
injections being approximately 6 hours apart (9am and 3pm). Once adolescent mice
had reached adulthood (PND 70), mice were evaluated for nicotine reward using
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conditioned place preference. Mice which received their first injections in adulthood
(PND 70) were evaluated seven weeks later (PND 120) in order to mimic the amount of
time between early adolescence and adulthood.
The precise protocol for conditioned place preference was the same as
previously described in Chapter 2. Briefly, mice have a pre-conditioning day which is a
drug free assessment of baseline preference in a three compartment chamber. This is
followed by three days of conditioning to either nicotine. Only one conditioning dose
of nicotine was used in this model (nicotine 0.5 mg/kg). This dose was chosen because
it was found to elicit preference for early adolescents and adults as demonstrated in
Figure 2 of Chapter 2. The final day of the paradigm is the same as day 1 and assesses
preference after the conditioning period. Preference scores are expressed as time spent
on drug-paired side minus time spent on saline-paired side. A positive number
indicated a preference for the drug-paired side, while a negative number indicated an
aversion to the drug-paired side. A number at or near zero indicated no preference for
either side.
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Early adolescence-Acute

One day; PND 28; 2 total injections

Early adolescence-Intermittent Every 3 days; PND 22, 25, 28, 31; 8 total injections
Early adolescence-Frequent

Every day; PND 22-28; 14 total injections

Late adolescence-Frequent

Every day; PND 50-56; 14 total injections

Adulthood-Frequent

Every day; PND 71-77; 14 total injections

Table 6. Time-course for conditioned place preference studies.
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Mecamylamine-Precipitated Withdrawal Studies
The timeline of nicotine withdrawal studies are outlined in Figure 20. Naïve
male mice were implanted with Alzet osmotic mini-pumps (model 2002- Alza
Corporation, Palo Alto, CA) filled with either (-)-nicotine (48 mg/kg/day or 24
mg/kg/day) or sterile physiological saline solutions. The mini-pumps were surgically
implanted s.c. under sterile conditions with pentobarbital anesthesia (35 mg/kg, i.p.).
An incision was made in the back of the animals, and a pump was inserted. Animals
were sutured and allowed to recover before being returned to their home cages. Eight
days following each mini-pump implantation, mice were injected s.c with 2.0mg/kg of
mecamylamine, a non-specific nicotinic antagonist, to precipitate withdrawal.
Withdrawal testing was conducted as previously described in Chapter 2. Briefly, mice
were assessed for withdrawal signs in a battery of four tests: 5 min for anxiety-like
behavior (on the elevated plus maze), 20 min observation of somatic signs (paw
tremors, head shakes, backing, body tremors, ptosis), hyperalgesia, and 30 min in
locomotor activity chambers.
One day following withdrawal testing, mice were lightly anesthetized using
ether and mini-pumps were removed. A small incision was made on the back of the
neck in order to remove the mini-pump and the wound was closed with a suture. Mice
were returned to their home cages in between surgeries and monitored on a weekly
basis. Each experimental group was implanted with a second mini-pump according to
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the timeline below (Figure 20). Withdrawal testing was conducted in the same manner
as previously described.

PND 28:
1st

PND 78:

withdrawal

2nd

Early Adolescent

PND 21:
1st

withdrawal

PND 70:
2nd

MP implanted

MP implanted

PND 78:

PND 57:
Late Adolescent

2nd

1st withdrawal

PND 49:

PND 70:

1st MP implanted

2nd withdrawal

withdrawal

PND 78:

PND 128:

1st withdrawal

2nd withdrawal

Adult
PND 120:

PND 70:
1st

MP implanted

2nd

MP implanted

Figure 20. Timeline for nicotine withdrawal studies. Nicotine mini-pumps were
implanted during early adolescence (PND 21), late adolescence (PND 49), or
adulthood (PND 70) for 7 days. Withdrawal testing was precipitated by
mecamylamine. After a recovery period, a second mini-pump was implanted and
withdrawal testing was conducted again in the same manner. MP=mini-pump,
PND = postnatal day
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Rubidium Efflux Studies
Both early adolescent and adult male mice were injected s.c. with
nicotine or saline for 7 days. Only one dose of nicotine (0.5 mg/kg) was used in these
studies based on previous behavioral results indicating that this dose was effective at
inducing long-term behavioral changes. The precise procedure for the rubidium efflux
assay was the same as previously described in Chapter 5 except that only two
concentrations of nicotine were utilized to stimulate the synaptosomes (1µM and
10µM).
C. Results
Effects of Adolescent Nicotine Exposure on Nicotine-Induced Rewarding Effects
Figure 21 presents the effects of early adolescent nicotine exposure on nicotine
reward in adulthood. As expected, when conditioned with saline in the CPP paradigm,
no preference was obtained. The nicotine challenge dose (0.5 mg/kg) did elicit a
preference for the drug-paired side after all patterns of exposure. In panels (a) and (b),
nicotine pretreatment in adolescence did not affect nicotine-induced reward in
adulthood. On the other hand, panel (c) demonstrates that at the moderate dose of 0.5
mg/kg nicotine, repeated nicotine exposure during early adolescence does enhance
nicotine reward in adulthood.
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Figure 21. Effect of early adolescent nicotine exposure on nicotine-induced reward
in adulthood. The y-axis represents preference score and the x-axis expresses
adolescent treatment followed by treatment in the CPP paradigm. Short term (a)
and intermittent (b) exposure to nicotine during early adolescence does not
enhance nicotine-induced conditioned place preference in adulthood; however
frequent exposure (c) to a moderate dose of nicotine during early adolescence
results in elevated nicotine-induced reward through a CPP model. * p<.05 from
respective saline control; # p<.05 from sal/nic group in the same graph; $ p<.05
from nic0.5/nic groups in acute (a) and intermittent (b) graphs.
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It has been proposed that early adolescence is the period which is particularly
susceptible to drug induced alterations in behavioral responses, but this age-specific
hypothesis has yet to be fully investigated. To examine if this hypothesis is valid, we
assessed the effects of nicotine exposure during various stages of development on
nicotine-induced reward using the CPP model. We also exposed a group of adult mice
to nicotine and tested them in the CPP model seven weeks later to see if the enhanced
reward was an effect of previous nicotine exposure alone or if the effect was indeed
unique to the adolescent phase. Results from these studies are presented in Figure 22.
Once again, in both the late adolescent and adult models, no preference was seen when
mice were conditioned with saline. Conditioning the mice with nicotine (0.5 mg/kg)
did result in a preference for the drug-paired side, but again no differences were
detected based on prior nicotine exposure.
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Figure 22. Effect of late adolescent and adulthood nicotine exposure on nicotineinduced reward. The y-axis represents preference score and the x-axis expresses
adolescent treatment followed by treatment in the CPP paradigm. Nicotine
exposure in late adolescence (a) and adulthood (b) does not elevated nicotineinduced rewarding effects later in development as measured by a CPP model. *
p<.05 from respective saline control; # p<.05 from sal/nic group in the same graph
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Repeated Nicotine Withdrawal Studies
The effects of adolescent nicotine exposure on nicotine withdrawal were also
investigated. For these experiments, mice were evaluated for withdrawal signs twice;
once during an adolescent phase and once as adults. Figure 23 shows withdrawal data
from a 7 day mini-pump infusion at a dose of 48 mg/kg/day in early adolescent and
adult mice. As expected from previous data shown in Chapter 2, adolescent mice (PND
21) displayed significantly attenuated somatic signs of withdrawal (Fig. 23a) as
compared to adult mice (PND 70). In a hyperalgesia measure (Fig. 23c), adults
demonstrated withdrawal while adolescents failed to do so. Anxiety-like behavior, an
affective sign of withdrawal, was also noted in adults, but not adolescents (Fig. 23b).
Furthermore, when adolescents had fully developed into adults (PND 70-2nd), they
continued to display an attenuation of somatic signs. There was also no indication of
withdrawal in the elevated plus maze or hot plate tests. Adult mice which were tested
again after 7 weeks of maturation (PND 120-2nd) continued to display withdrawal in all
four measures tested.
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Figure 23. Effect of early adolescent nicotine exposure on nicotine withdrawal.
Mice were tested for withdrawal as previously described. The x-axis denotes the
age of mice upon MP implantation. PND 21=early adolescent; 1st withdrawal;
PND 70 (2nd)=2nd withdrawal for early adolescent group; PND 70=adult mice; 1st
withdrawal; PND120 (2nd)=2nd withdrawal for adult group. * p<0.05 from saline
group and #p<0.05 from adult nicotine treatment. Each point represents the mean
± S.E. of 12 mice. MP=mini-pump, PND = postnatal day
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SS

EPM

HP

LA

PND 21- sal/sal 4 ± 1

34.8 ± 4.7

11.3 ± 1.8

952 ± 77

PND 21-nic/sal

5±1

29.3 ± 5.9

9.5 ± 0.8

1141 ± 42

PND 70 (2nd)
sal/sal
PND 70 (2nd)
nic/sal
PND 70-sal/sal

2±0

30.1 ± 1.9

10.1 ± 0.6

1053 ± 54

3±1

31.7 ± 1.4

9.5 ± 0.4

1101 ± 76

6±3

41.5 ± 0.6

9.3 ± 1.3

1102 ± 56

PND 70-nic/sal

8±1

33.6 ± 6.0

9.6 ± 0.5

1154 ± 47

PND 120 (2nd)
sal/sal
PND 120 (2nd)
nic/sal

3±0

27.8 ± 2.5

8.7 ± 0.3

1055 ± 41

3±0

32.7 ± 2.3

8.1 ± 0.3

1006 ± 36

Table 7. Summary of control data for early adolescent repeated nicotine
withdrawal study (48 mg/kg/day). Data are represented as the mean response ±
S.E. of 12 mice. No significant differences were observed in any of the control
groups. PND = post natal day; SS = somatic signs; EPM = elevated plus maze; HP
= hot plate; LA = locomotor activity.
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One of the goals of this study was to determine if all phases of adolescence
represent a unique period in which nicotine exposure can lead to long-lasting behavioral
effects or if this phenomenon was unique to early adolescence. Therefore, we repeated
the above study using late adolescent mice which is shown in Figure 24. Unlike the
early adolescent mice, the late adolescent phase did not result in the same vulnerability
to lasting behavioral adaptations. Late adolescent mice displayed withdrawal signs
consistent to those of adult mice in that there were no significant differences in any of
the tests. Exposure to nicotine during late adolescence did not attenuate withdrawal
signs once the animals had developed into adulthood.
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Figure 24. Effect of late adolescent nicotine exposure on nicotine withdrawal.
Mice were tested for withdrawal as previously described. The x-axis denotes the
age of mice upon MP implantation. PND 49=late adolescent; 1st withdrawal; PND
70-2nd=2nd withdrawal for late adolescent group; PND 70=adult mice; 1st
withdrawal; PND 120-2nd=2nd withdrawal for adult group. * p<0.05 from saline
group and #p<0.05 from adult nicotine treatment. Each point represents the mean
± S.E. of 12 mice. MP=mini-pump, PND = postnatal day
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SS

EPM

HP

LA

PND 49- sal/sal 4 ± 0

24.1 ± 5.4

8.5 ± 0.5

1247 ± 103

PND 49-nic/sal

3±1

22.4 ± 4.4

8.2 ± 0.9

1186 ± 103

PND 70 (2nd)
sal/sal
PND 70 (2nd)
nic/sal
PND 70-sal/sal

3±0

29.5 ± 2.1

9.2 ± 0.4

1176 ± 88

3±1

28.0 ± 3.0

8.4 ± 0.8

1097 ± 52

4±0

33.2 ± 2.7

9.1 ± 0.5

1078 ± 54

PND 70-nic/sal

3±1

30.3 ± 3.2

8.6 ± 0.7

1105 ± 70

PND 90 (2nd)
sal/sal
PND 90 (2nd)
nic/sal

3±1

29.8 ± 3.1

8.4 ± 0.9

1098 ± 48

2±2

34.1 ± 2.9

9.0 ± 1.0

1147 ± 63

Table 8. Summary of control data for late adolescent repeated nicotine withdrawal
study (48 mg/kg/day). Data are represented as the mean response ± S.E. of 12 mice.
No significant differences were observed in any of the control groups. PND = post
natal day; SS = somatic signs; EPM = elevated plus maze; HP = hot plate; LA =
locomotor activity.
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Another important component of our nicotine withdrawal studies was to
examine the duration of adolescent nicotine exposure. In this study, early adolescent
mice were only exposed to nicotine for 3 days prior to precipitating withdrawal. In
somatic signs (Fig. 25a), withdrawal signs were noted in both age groups, but early
adolescent mice continued to display a significant decrease in withdrawal intensity as
compared to adults. Only adults displayed withdrawal signs in the elevated plus maze,
hyperalgesia, and hyperactivity tests. Once again, when early adolescent mice were
allowed to develop to adults (PND 70-2nd), they retained their attenuated level of
somatic withdrawal signs.
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Figure 25. Three day model of early adolescent nicotine exposure on nicotine
withdrawal. Mice were tested for withdrawal as previously described in the
methods section. The x-axis denotes the age of mice upon MP implantation. PND
21=late adolescent; 1st withdrawal; PND 70(2nd)=2nd withdrawal for late adolescent
group; PND 70=adult mice; 1st withdrawal. * p<0.05 from saline group and
#p<0.05 from adult nicotine treatment. Each point represents the mean ± S.E. of
12 mice. MP=mini-pump, PND =postnatal day
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Nicotine dose was also considered in these studies since it is common for
adolescents to smoke less than adults. In this final study, we repeated the 7 day model
of exposure but lowered the nicotine mini-pump dose to 24 mg/kg/day. Once again, we
were able to consistently precipitate withdrawal in this model. Only adult mice
displayed significant withdrawal signs in the plus maze and hot plate tests. Similar to
our higher dose model, both age groups displayed significant somatic withdrawal signs,
but adolescents showed attenuation in the withdrawal intensity (Fig. 26a). After
maturing to adults, mice which were previously exposed to nicotine as adolescents
continued to show a reduction in somatic signs.
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Figure 26. Effect of a low dose of early adolescent nicotine exposure on nicotine
withdrawal. Mice were tested for withdrawal as previously described with MP
dose reduced to 24 mg/kg/day. The x-axis denotes the age of mice upon MP
implantation. PND 21=early adolescent; 1st withdrawal; PND 70 (2nd)=2nd
withdrawal for early adolescent group; PND 70=adult mice; 1st withdrawal;
PND120 (2nd)=2nd withdrawal for adult group. * p<0.05 from saline group and
#p<0.05 from adult nicotine treatment. Each point represents the mean ± S.E. of
12 mice. MP=mini-pump, PND = postnatal day
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SS

EPM

HP

LA

PND 21- sal/sal 3 ± 0

33 ± 2.6

7.6 ± 0.5

1182 ± 48

PND 21-nic/sal

2±1

32.3 ± 3.5

7.5 ± 0.4

1072 ± 25

PND 70 (2nd)
sal/sal
PND 70 (2nd)
nic/sal
PND 70-sal/sal

3±0

29.5 ± 2.3

7.4 ± 0.4

1293 ± 36

2±1

34.6 ± 3.5

8.8 ± 1

1116 ± 42

3±0

31.6 ± 2.2

8.2 ± 0.5

1233 ± 75

PND 70-nic/sal

2±0

31.5 ± 1.9

7.7 ± 0.5

1173 ± 15

PND 120 (2nd)
sal/sal
PND 120 (2nd)
nic/sal

2±0

28.9 ± 2.1

8.0 ± 0.2

1265 ± 78

3±1

33.1 ± 2.7

7.3 ± 0.5

1221 ± 35

Table 9. Summary of control data for repeated nicotine withdrawal (24
mg/kg/day). Data are represented as the mean response ± S.E. of 12 mice. No
significant differences were observed in any of the control groups. PND = post
natal day; SS = somatic signs; EPM = elevated plus maze; HP = hot plate; LA =
locomotor activity.
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In Chapter 5, our data indicated that naïve adolescent mice demonstrated an
enhanced functional response of neuronal nAChRs as compared to adult receptors. We
wanted to investigate the effects of adolescent nicotine exposure to see if this treatment
would result in long-lasting effects of receptor function that correlate with behavioral
changes. Figure 27 shows the results of both adolescent and adult synaptosome
stimulation after pretreatment with either nicotine or saline 7 weeks prior to testing.
The cortex, hippocampus, and thalamus regions showed a dose-dependent increase in
nAChR function between the 1µM and 10µM concentrations of nicotine. In three out of
four regions (all except cortex), the mice which were pretreated with nicotine 0.5 mg/kg
in adolescence showed a significant elevation in nAChR function as compared to their
saline controls. In contrast, those mice treated with nicotine in adulthood did not
demonstrate any differences as compared to the saline group. At the 10µM
concentration, there was a significant increase in the adolescent mice receiving nicotine,
but adult mice showed no differences based on pretreatment.
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Figure 27. The effect of early adolescent nicotine exposure on nAChR function in
adulthood. Two concentrations of nicotine are plotted on the x-axis and total area
under the curve (AUC) is represented on the y-axis. Bars represent adolescent and
adult mice which were pretreated with either saline or nicotine. Results are
expressed as mean AUC ± S.E. * p<0.05 from respective saline control; # p<.05
from Adult-Nic group at same concentration.
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D. Discussion
Data from these studies show that adolescent nicotine exposure affects both
nicotine reward and withdrawal in adulthood. In the CPP model we have shown that
early, but not late adolescent nicotine exposure elevates nicotine reward in adulthood in
a dose- and duration-dependent manner. Mice which were exposed to a moderate dose
of nicotine (0.5 mg/kg) in a frequent administration pattern demonstrated enhanced
rewarding effects of nicotine as adults. The lower dose of nicotine (0.1 mg/kg) as well
as less frequent exposure patterns did not result in the same level of enhanced reward.
To eliminate the possibility that nicotine exposure can induce alterations in behavior at
any age and demonstrate the selectivity of these changes, we also exposed adult mice to
nicotine and tested them in the CPP model 7 weeks later. However, enhancement of
rewarding effects was not seen using this paradigm. This result shows that moderate
exposure to smoking during adolescence can have significant consequences in
adulthood. Furthermore, it supports earlier data suggesting that early adolescence (PND
24-31) is a unique period for vulnerability to nicotine dependence.
On the other hand, nicotine exposure and withdrawal during adolescence had
long-lasting effects on nicotine withdrawal in adulthood. Both short term (3 days) and
long term (7 days) nicotine exposure caused persistent decreases in withdrawal signs
once mice had reached adulthood. In addition, both a high (48 mg/kg/day) and low (24
mg/kg/day) dose of nicotine resulted in this same attenuation. However, we have again
demonstrated that this phenomenon is unique to the early adolescent phase since late
adolescent nicotine exposure did not result in a persistent decrease in withdrawal signs.

124
Interestingly, our results indicate that early adolescent, but not adulthood,
nicotine exposure causes an elevation of nAChR function 7 weeks following injections
(in adulthood). It appears that when nicotine is given in adolescence there are longlasting effects at the receptor level which translate into changes in behavioral response.
Data from this study and from the previous rubidium efflux study in Chapter 5 offer a
potential mechanism by which nicotine induced persistent alterations in levels of
dependence. However, mechanisms of the persistent increase in receptor function are
not clear since binding studies were not conducted.
Our data imply that early adolescence is a critical period in becoming dependent
on nicotine for a lifetime. Even short periods of exposure to cigarette smoking, which
are often seen in the adolescent population, could have long-lasting and detrimental
effects on smoking behavior. Studies from the World Health Organization show
evidence that around 50% of those who start smoking in adolescent years go on to
smoke for 15 to 20 years (2002). These statistics should indicate the critical nature of
providing influential prevention messages at an early age. The longer a child or
teenager is prevented from smoking or exposure to nicotine, the higher the chance of
preventing lifetime dependence. Furthermore, the issue of secondhand smoking should
be considered. Indeed, human studies show that adolescents who are exposed to
secondhand smoke are more likely to develop chronic health issues such as asthma
(Tager 2008) and earaches (Lee et al. 2003), but how this type of exposure affects
nicotine dependence in those children has yet to be explored. Our results could have
important implications in prevention messages and even policy making.

THE EFFECTS OF ADOLESCENT NICOTINE EXPOSURE ON COCAINEINDUCED BEHAVIORAL RESPONSES

A. Introduction
In addition to adolescent nicotine exposure increasing lifetime nicotine
dependence, several studies have investigated the possibility of nicotine serving as a
drug which will lead adolescents to further illicit drug use later in life. Indeed, nicotine
is one of the first and most commonly abused drugs in adolescence and is known to be a
strong predictor of subsequent alcohol and other drug abuse (Kandel et al. 1992).
Furthermore, the adolescent period is one of dramatic structural changes involving
synaptic pruning, apoptosis, and cell migration (Huttenlocher 1984; Lidow and Rakic
1992). Adolescent nicotine exposure is thought to cause alterations in brain structure
and function as well as changes in the mesolimbic reward pathway which is highly
involved in drug addiction (Slotkin 2004). Specifically, researchers have demonstrated
nicotine’s ability to alter important neurotransmitter systems such as the serotonergic,
glutaminergic, cholinergic, and dopaminergic among others (Trauth et al. 2000; Xu et
al. 2002; Adriani et al. 2004). For example, adolescent rats (PND 30 to PND 47) given
nicotine via mini-pump demonstrated a decrease in serotonergic receptors (5HT2) in the
hippocampus and cerebral cortex (Xu et al. 2002). Adriani et al. (2004) measured
levels of AMPA GluR2/3 subunits, thought to be involved in the control of addictive
behaviors two months following adolescent nicotine exposure. The results showed a
dose-dependent downregulation of these subunits in the striatum and hippocampus, but
comparable exposure during adulthood had either opposite or no effects.
These structural alterations often lead to changes in behavioral responses to
other drugs of abuse as well. For example, adolescent nicotine exposure resulted in
long-lasting changes in the rewarding properties of cocaine and alcohol (Kelley and
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Middaugh 1999; Kelley and Rowan 2004).

Kelley and Rowan (2004) found that

adolescent mice exposed to nicotine (0.3, 1.0, or 3.0 mg/kg) from PND 25-57 showed a
decreased in response to cocaine’s rewarding effects when tested after a 28 day drugfree period. On the other hand, mice demonstrated an increased response to cocaine’s
locomotor activating effects. Additionally, McQuown et al. (2006) showed that in rats,
i.v. pretreatment with nicotine (0.03 mg/kg/0.1ml) in adolescence for 4 days resulted in
enhanced cocaine-reinforced responding.
Cocaine and nicotine share common neuronal mechanisms which could suggest
that adolescent nicotine exposure can result in alterations to behavioral responses to
cocaine. Results of three earlier studies suggest such implications (Kelley and
Middaugh 1999; Kelley and Rowan 2004; McQuown et al. 2006). However, these
previous studies have not investigated these effects under the same conditions.
Moreover, they have not addressed important considerations such as dose, duration of
exposure, and route of administration. In this set of studies, we have characterized the
effects of adolescent nicotine exposure on three separate cocaine-induced behaviors in
mice which represent different aspects of cocaine dependence.

It is important to

examine a variety of behaviors in the same species and under the same pretreatment
conditions in order to gain a more complete understanding of these effects. First, we
examined both high and low doses of nicotine, as well as duration of nicotine exposure,
on cocaine-induced reward using the CPP model. Second, we evaluated the effects of
these parameters on cocaine’s acute effects using locomotor activity testing. Finally,
we investigated locomotor sensitization to cocaine in pretreated animals since this
model has been established as a good indicator of neuronal plasticity effects (Robinson
and Becker 1986).
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B. Methods
Drugs
(-)-Nicotine bitartrate and mecamylamine hydrochloride were purchased from
Sigma Chemical Company (Milwaukee, WI). All doses are expressed as free base.
Cocaine was provided by the National Institute for Drug Abuse.
Adolescent Injection Protocol
Mice received nicotine during early adolescence (PND 21-31), late adolescence
(PND 49-59) or adulthood (PND 70+). Based on studies in Chapter 6, we choose to
only use either an acute pattern (1 day) or a repeated pattern of exposure (7 days) in
duration. Nicotine (0.1 and 0.5 mg/kg) or saline was administered s.c. twice daily with
injections being approximately 6 hours apart (9am and 3pm). Mice were kept in their
home cages and allowed to mature until they had reached adulthood at which point they
were evaluated in paradigms as described below.
Conditioned Place Preference Studies
Once adolescent mice had reached adulthood (PND 70), they were tested for
cocaine reward using conditioned place preference. The precise protocol for
conditioned place preference was the same as previously described in Chapter 2.
Briefly, mice have a pre-conditioning day which is a drug free assessment of baseline
preference in a three compartment chamber.

This is followed by three days of

conditioning to either nicotine or cocaine. Only one conditioning dose of cocaine was
used in this model (10 mg/kg i.p.). The final day of the paradigm is the same as day 1
and assesses preference after the conditioning period. Preference scores are expressed
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as time spent on drug-paired side minus time spent on saline-paired side. A positive
number indicated a preference for the drug-paired side, while a negative number
indicated an aversion to the drug-paired side. A number at or near zero indicated no
preference for either side.
Acute Locomotor Activity
Another group of mice were tested for cocaine-induced hyperactivity using
locomotor chambers after reaching adulthood. Dose-response curves were generated
for each pretreated group (saline, nicotine 0.1 mg/kg, or nicotine 0.5 mg/kg). Mice
were injected i.p with saline or various doses of cocaine (5, 10, and 15 mg/kg) and then
placed into individual Omnitech photocell activity cages (Columbus, OH; 28 x 16.5 cm)
10 min after injection. Mice were allowed to habituate to the chamber for 5 minutes
before data collection began. Interruptions of the photocell beams (two banks of eight
cells each) were then recorded for the next 30 min in 10 min intervals. Data are
expressed as number of photocell interruptions.
Cocaine Locomotor Sensitization
For this study, only early adolescent mice (PND 22-28) were pretreated with
saline or nicotine (0.5 mg/kg) injections. Our protocol was based on the study by Biala
(2003). Briefly, once the mice had reached PND 70, a 13 day cocaine sensitization
protocol began. On day 1, mice were given a saline injection (i.p.) and placed into
locomotor activity chambers for a 30 minute habituation period.

Immediately

following, mice were removed from the chambers and activity counts were recorded.
Mice were randomly divided into three groups: saline-saline, saline-cocaine, and
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cocaine-cocaine (groups represent the acquisition day drug followed by the challenge
day drug). Mice were then given another injection of either saline or cocaine 20 mg/kg
(i.p.), depending on the assigned group, and placed in the chambers again for a 30
minute acquisition period. This procedure was repeated on days 2-5. Days 6-12 were
considered a drug free week in which the animals were not given injections or exposed
to the chambers. On day 13, mice were tested again in the same manner as described
for days 1-5, but cocaine mice received a challenge dose of cocaine of 5 mg/kg (i.p.).
Counts were recorded after a 30 minute test period.
C. Results
Effect of Adolescent Nicotine Exposure on Cocaine-Induced Conditioned Place
Preference
Figures 28-30 show the results of our cocaine-induced CPP study after mice had
received nicotine at various stages of development. In Figure 28, mice received either
an acute (1 day) or repeated (7 day) exposure to nicotine during early adolescence. All
mice which were conditioned with cocaine in the CPP model developed significant
preference for the drug-paired side as compared to their respective saline controls.
Interestingly, mice which had a 7 day exposure to the higher dose of nicotine (0.5
mg/kg), displayed a significantly enhanced level of preference as compared to those
mice which were pretreated with saline. In addition, this group showed significantly
enhanced preference as compared to the same treatment group in the late adolescent
study (Figure 29) as indicated by the $ symbol in Figure 28. On the other hand, the
lower dose of nicotine (0.1 mg/kg) did not produce a significant enhancement of
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reward. No differences were noted in the acute exposure paradigm. The results of
cocaine-induced CPP following late adolescent and adult nicotine exposure are shown
in Figures 29 and 30 respectively. As expected, all mice conditioned with cocaine
during CPP testing displayed significant preference for the drug paired side. In contrast
to data in early adolescent mice, late adolescent mice did not demonstrate any
significant differences based on pretreatment status in either the acute or repeated
exposure protocol. Similarly, mice which received nicotine exposure during adulthood
displayed approximately equal levels of preference for cocaine despite varying
pretreatment groups. These results indicate that the enhancement of cocaine-induced
preference is unique to the early adolescent period and is not due to previous nicotine
exposure alone.
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Figure 28. Effects of early adolescent nicotine exposure on cocaine-induced CPP in
adulthood. The y-axis represents preference score and the x-axis expresses
adolescent treatment followed by treatment in the CPP paradigm. Repeated
nicotine exposure in early adolescence elevated cocaine-induced rewarding effects
in adulthood. * p<.05 from respective saline control; # p<.05 from sal/nic group in
the same graph; $ see text in results section
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Figure 29. Effects of late adolescent nicotine exposure on cocaine-induced CPP in
adulthood. The y-axis represents preference score and the x-axis expresses
adolescent treatment followed by treatment in the CPP paradigm. * p<.05 from
respective saline control
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Figure 30. Effects of adulthood nicotine exposure on cocaine-induced CPP 7 weeks
later. The y-axis represents preference score and the x-axis expresses adolescent
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saline control
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Effects of Adolescent Nicotine Exposure on Cocaine-Induced Hyperactivity
In this study, we examined the effects of adolescent nicotine pretreatment on
cocaine’s acute effects using a locomotor activity test. Figures 31-33 show the results
from these studies. Figure 31 depicts the results from both an acute (1 day) and
repeated (7 day) nicotine exposure pattern during early adolescence. No changes were
observed after acute exposure; however those mice which were pretreated with the
higher dose of nicotine (0.5 mg/kg) in early adolescence displayed a significant
elevation in cocaine-induced hyperactivity as compared to those pretreated with saline
or a low dose of nicotine (0.1 mg/kg). Figures 32 and 33 show the results from studies
where pretreatment occurred in late adolescence and adulthood respectively. No
significant differences were seen based on pretreatment injections in either age group
confirming that the effect seen in Figure 31 is unique to the early adolescent period.
Interestingly, saline treated mice undergoing repeated nicotine exposure displayed a
trend for slightly decreased activity. This was consistent across all three age groups and
is likely due to the stress of repeated injections since this behavior was not seen after
acute exposure.
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Figure 31. Cocaine-induced hyperactivity following nicotine exposure in early
adolescence. Mice were pretreated with saline or nicotine during early adolescence
either acutely (1 day) or repeatedly (7 days) and were tested for cocaine
hyperactivity in adulthood. n=6/group *p<0.05 from saline pretreatment.
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Figure 32. Cocaine-induced hyperactivity following nicotine exposure in late
adolescence. Mice were pretreated with saline or nicotine during late adolescence
either acutely (1 day) or repeatedly (7 days) and were tested for cocaine
hyperactivity in adulthood. n=6/group
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Figure 33. Cocaine-induced hyperactivity following nicotine exposure in
adulthood. Mice were pretreated with saline or nicotine adulthood either acutely (1
day) or repeatedly (7 days) and were tested for cocaine hyperactivity 7 weeks later.
n=6/group
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Effects of Adolescent Nicotine Exposure on Locomotor Sensitization to Cocaine
Finally, results from Figure 34 show our study examining the effects of early
adolescent nicotine treatment on cocaine-induced behavioral sensitization. Mice which
were pretreated with nicotine in adolescence are shown in the solid bars while saline
pretreated mice are shown in the non-solid bars. During the acquisition period, mice
which were treated with cocaine (20 mg/kg) demonstrated enhanced locomotor activity
as expected with no differences due to adolescent pretreatment (*p<.05 as compared to
sal-sal). On challenge day two groups received an injection of cocaine i.p. (5 mg/kg).
Both saline and nicotine pretreated mice who were treated with cocaine during
acquisition displayed enhanced locomotor activity as compared to those mice treated
with saline during acquisition. However, mice which were pretreated with nicotine in
adolescence showed a significant elevation in cocaine-induced locomotor activity as
compared to saline pretreated animals. These results show that we were able to induce
locomotor sensitization to cocaine and that early adolescent nicotine exposure enhances
this effect.
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Figure 34. Cocaine-sensitization in ICR male mice. Early adolescent mice were
pretreated with either saline (non-solid bars) or nicotine (solid bars) for 7 days and
were tested for cocaine-induced locomotor sensitization in adulthood. Treatment
groups are represented by acquisition drug-challenge drug in the legend (ex. salcoc = saline during acquisition and cocaine on challenge day) *p<.05 from sal-sal
control on the same day; # p<.05 from sal-coc group; $p<.05 from saline
pretreated coc-coc group.
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D. Discussion
The use of tobacco often begins during the adolescent period. Furthermore, it is
well-established that the commencement of smoking at a young age correlates with a
higher prevalence of nicotine dependence in adulthood (Colby et al. 2000; Kandel and
Chen 2000). However, there is not as much evidence for the effects of cigarette
smoking on dependence for other drugs of abuse. Some studies have shown that
nicotine is a strong predictor of subsequent drug use (Kandel et al. 1992), but the exact
mechanism behind these changes is unknown.
Specifically, we have chosen to investigate the effects of adolescent nicotine on
cocaine-induced behavior. To date, studies have shown mixed results in this regard, but
several factors, such as different models, strains, and species, could contribute to these
differences. We decided to utilize several paradigms in order to investigate the
consistency of nicotine’s effects in mice. In a CPP model of reward, our results
demonstrated that the higher dose of nicotine (0.5 mg/kg) given for 7 days enhanced
preference for a cocaine-paired environment.

In contrast to our findings, Kelley and

Rowan (2004) found that C57BL/6J mice demonstrated a decrease in cocaine-induced
reward as measured by CPP after 25 days of adolescent nicotine exposure.

This

discrepancy could be accounted for by the difference in mouse strain (C57BL/6J vs.
ICR) as well as length of exposure (25 days vs. 7 days). Interestingly, they noted that
this exposure led to an increase in cocaine’s motor activating effects which is in
agreement with the results from our acute locomotor study. Other studies in rats which
have utilized a shorter duration of adolescent nicotine exposure have found that the
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rewarding effects of cocaine are enhanced. Indeed, McQuown et al. (2006) reported
that a low dose of nicotine treatment for four days in adolescence enhanced the
reinforcing effects of cocaine in an i.v. self-administration model using a FR1 schedule.
Similarly, rats given nicotine from PND 35 to 44 demonstrated an enhancement of
cocaine-induced reward using a CPP paradigm (McMillen et al. 2005).
Our findings in the CPP model strongly suggest that nicotine during adolescence
may act to cross-sensitize the brain to cocaine’s rewarding effects. Indeed adolescence
is a unique period of brain maturation and development. Much of the motivational
circuitry controlling reward and reinforcement is still undergoing alterations (Chambers
et al. 2003). Specifically, dopaminergic projections from the PFC to the NAc may be
influenced by this exposure which would have effects on the pleasurable experiences
associated with drugs of abuse such as cocaine. In addition, nicotine may be acting
directly on the maturing dopamine system (Andersen 2003). It has been established that
nicotinic receptors play in a role in regulation of dopaminergic neuronal projections
(Cragg 2006) and it is possible that nicotine exposure during a critical period such as
adolescence may yield long-lasting changes in this system.

Indeed, quantity of

dopamine transporters will be important to examine since this serves as a major target
for cocaine.
Also in agreement with our reward studies is data from our locomotor
sensitization model which is linked to the establishment of drug dependence. We have
found that a 7 day nicotine pretreatment in early adolescence enhanced sensitization to
cocaine on challenge day as compared to saline pretreatment. To our knowledge, this is
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the first study to examine the effect of adolescent nicotine exposure on cocaine-induced
sensitization in mice. These results suggest that early nicotine exposure may correlate
with an increased risk of relapse after a period of withdrawal and further implicate a
role for dopamine in the cross-sensitization to other drugs of abuse. Implications to
human studies are also evident. For example, adolescents who had previously smoked
cigarettes were found to have higher initial “wanting” scores and were more likely to
become cocaine-dependence than non-smokers (Lambert et al. 2006).
It is of interest to note that an acute exposure to nicotine did not elicit the same
effects as a repeated exposure pattern in our CPP and acute locomotor models. This
finding implies that long-lasting alterations in neurochemical systems require activation
of targets involved in synaptic plasticity or gene expression. The importance of this
observation will be further addressed in the general discussion. Taken together, results
from this chapter support the hypothesis that adolescent nicotine exposure is able to
enhance susceptibility to other drugs of abuse as well. Once again, this result stresses
the importance of preventing adolescent experimentation with tobacco as it can rapidly
cause persistent changes in drug-induced behavioral responses.

GENERAL DISCUSSION
A. Rationale and Summary of Overall Hypothesis
In the United States, smoking-related illnesses cause more than 430,000 deaths
and cost more then $150 billion annually (CDC MWRR 2002). Most of these lifetime
smokers begin smoking during adolescence (Chassin et al. 1990). It is common for
teenagers to explore tobacco and alcohol use during the developmental phase of
adolescence; however many adolescent smokers show loss of autonomy over nicotine
after just a few cigarettes (DiFranza 2002) despite the desire to quit (Eissenburg and
Balster 2000). Factors such as cravings and withdrawal symptoms are frequently cited
by this age group as reasons for unsuccessful quit attempts (Johnson 1982; Biglan and
Lichtenstein 1984).

Indeed, Colby et al. (2000) wrote a review suggesting that the

current methods and approaches to smoking cessation in adolescence need further
attention since successful cessation rates are modest.

It is imperative that better

smoking cessation therapies and prevention messages are targeted specifically toward
adolescents in order to decrease the number of smokers in the United States.
While the issue of adolescent nicotine dependence has recently become a focus
of addiction research, there is still much work that needs to be done. To date, we do not
fully understand the mechanisms which underlie an adolescent’s heightened
vulnerability to nicotine dependence. Furthermore, the scope and extent of the changes
in the neurobiology of adolescent smokers has yet to be determined. Learning more
about these changes will help us to target key areas which are affected by nicotine and
to develop therapies which address these issues. To this aim, our studies have focused
143
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on the mechanisms of change which are involved in alterations of nicotine dependence.
Specifically, we decided to center our studies on the initial target of nicotine, the
nicotinic acetylcholine receptor in the brain.
The work in this dissertation addresses three areas of research and contributes to
the further understanding of adolescent nicotine dependence. First, we performed a full
characterization of nicotine dependence in various age groups and both sexes to address
age- and sex-related disparities. Second, we examined possible molecular mechanisms
which may underlie these differences. Third, we sought to investigate the effects of
adolescent smoking on future, and perhaps long-term, drug abuse. Overall, we
hypothesized that vulnerability to nicotine dependence in adolescence is due to a shift in
the balance between two key components of nicotine dependence, namely reward and
withdrawal, and that this shift is due to nicotine-induced, region-specific changes in the
brain. Furthermore, we predicted that nicotine exposure in adolescence would lead to
long lasting changes in nicotine-induced behavior as well as dependence on other drugs
of abuse.
B. Nicotine reward and withdrawal are age- and sex- dependent
Studies from our first specific aim demonstrate that two key aspects of nicotine
dependence, reward and withdrawal, are both age- and sex-dependent.

To our

knowledge, this is the first study to characterize both of these variables under the same
experimental conditions and in parallel. The data from our studies show that early
adolescence is a particularly vulnerable period for developing nicotine dependence, yet
this susceptibility differs for each sex.

In adolescent males, the rewarding effects of
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nicotine are enhanced as compared to adults while withdrawal signs are attenuated
(Figures 2, 4, 6, and 8). In contrast, we found that females demonstrated enhanced
nicotine withdrawal effects, but an overall decrease in nicotine reward sensitivity
(Figures 2, 5, 7, and 9). There are important implications for these findings in the realm
of nicotine dependence. In adolescent females, it appears that withdrawal effects are
the greater contributor to long-term smoking behavior because they prohibit effective
smoking cessation attempts. In fact, in agreement with our rodent studies, clinical
findings report that women are less likely to quit smoking successfully due to high
withdrawal effects (Leventhal et al. 2007). On the other hand, male data revealed that
adolescents are more likely to continue cigarette smoking due to the reinforcing effects
of the drug as shown by an increased sensitivity to low doses of nicotine in the CPP
model.

These studies show that smoking cessation therapies need to target the

molecular mechanisms which are responsible for the most reinforcing stimuli. In males,
key pathways involved in nicotine reward need to be the focus of therapeutic strategies,
while in females, targeting the nicotinic receptors which are highly involved in
withdrawal effects may be more critical.
In addition to sex-dependent differences, our work clearly revealed agedependent differences in the intensities of important aspects of nicotine dependence.
For example, we have shown that adolescents, given the same level of nicotine as
adults, do express withdrawal signs; an important observation from a clinical
perspective. Although the intensity of nicotine withdrawal in adolescents is less than
that of the adult in males, this finding still confirms that adolescent smokers show signs
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of nicotine dependence.

It is also interesting to note that in practice, adolescent

smoking intake behavior is not consistent with that of adults and it is likely that their
actual nicotine intake is lower. In this regard it is difficult to make a valid assessment
of how withdrawal symptoms contribute to dependence. In addition to withdrawal
signs, we have shown that during adolescence positive rewarding effects of nicotine are
enhanced in the male sex. It could be argued that these positive effects contribute more
to the enhanced vulnerability to nicotine addiction in males since there is a high desire
for immediate positive reinforcement without proper assessment of risk during the
adolescent period.
C. Early adolescence presents a unique period of vulnerability to drug dependence
Several studies have demonstrated that adolescence as a whole is an important
period in the development of drug dependence. However, not many studies have
examined the specific phases of adolescence and how each plays a role in this enhanced
vulnerability. Our work is the first to investigate the importance of adolescent phase in
both reward and withdrawal models. These studies were only conducted in males as
this sex was chosen to be the focus of our project. Our findings confirm that in male
mice, the early adolescent phase is a unique time of development which is particularly
vulnerable to the effects of nicotine. In a CPP model, only early adolescent mice
demonstrate an increased sensitivity to low doses of nicotine (Figure 14). In addition,
data from Figure 15 reveal that late adolescent mice exhibit the same intensity of
withdrawal as adults while early adolescent have decreased withdrawal intensity in both
somatic and affective signs. In agreement with our work, several studies in rats have
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shown that only early adolescent rodents develop preference to nicotine (Adriani et al.
2002; Belluzzi et al. 2004). Additionally, O’Dell et al. (2006) previously reported that
somatic signs of nicotine withdrawal are attenuated in early adolescent male rats. Our
research confirms that finding in mice and adds to it by confirming this decrease in two
additional somatic signs and one affective sign.
These data contribute to the understanding of previous human research which
indicates that the initiation of smoking at an early age is known to lead to increased
addiction and decreased cessation rates (Colby et al. 2000; Kandel and Chen 2000).
Indeed, since the brain has not reached its full maturation, it has a heightened
vulnerability to aspects of nicotine dependence which will lead to life-long smoking
behavior. In summary, these findings convey the importance of delaying teenage
smoking as long as possible, if not preventing it completely, through better prevention
messages. Additionally, clinical trials must include these younger age groups in their
studies. It will also be beneficial to address the interactions of pubertal status and
hormone development with such clinical treatment strategies as the effectiveness of
treatment may change with these factors.
D. Pharmacological and Molecular Mechanisms Involved in Nicotine Dependence
Chapters 3 and 5 of this dissertation address specific in vivo and in vitro
mechanisms which may play a role in the enhanced propensity for adolescents to
become dependent on nicotine. In Chapter 3, we assessed both the acute sensitivity to
nicotine as well as tolerance to nicotine in adult and adolescent mice of both sexes.
These models were chosen because of the insight they provide into the differences
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observed in previous behavioral models. Acute sensitivity models allow a distinction in
immediate response to a drug which has implications for disparities in nicotinic receptor
function and activation. Also, tolerance, or the capacity of the body to become less
responsive to a drug following chronic use, is a phenomenon which has been shown to
contribute to nicotine dependence (Damaj and Martin 1993; Robinson et al. 1996).
Our data show that following acute treatment with nicotine, adolescent male
mice displayed a nicotine-induced antinociception compared to adults in the tail-flick
test. The implication of this finding suggests that predisposition to maintain use of
nicotine in adolescent males may be due to the lessening of aversive effects due to
decreased sensitivity to the drug. However, since no general decrease in nicotine’s
acute effects was found in our studies this implies that acute sensitivity to nicotine is not
a major factor. Similarly, we observed a higher degree of tolerance to nicotine-induced
antinociception in adolescent male mice in the hot-plate assay suggesting that this age
group would need to increase their nicotine intake in order to attain the same level of
effect as an adult. This would lead to an increased smoking behavior and higher
nicotine intake in adolescence resulting in increased vulnerability to nicotine
dependence. Once again, the other two measures of tolerance did not show significant
results in the same manner implying that tolerance is only playing a minor role in
adolescent vulnerability.
In females, we observed an opposing trend in both acute sensitivity and
tolerance as compared to males. Increased sensitivity to nicotine was noted in one
analgesic assay and the hypothermia test in adolescents. Moreover, a lower degree of
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tolerance was detected in adolescents in the hypothermia test, but no changes were seen
in antinociceptive measures. Since not all tests for acute sensitivity and tolerance to
nicotine reflected similar shifts, we can assume that these mechanisms are not likely to
be substantial contributors to age-dependent differences in nicotine reward and
withdrawal.
In addition to behavioral mechanisms, it is probable that molecular mechanisms
are involved in age-related differences in nicotine dependence. Indeed, alterations in
receptor number and function as well as differences in downstream signaling would
affect pharmacological responses to nicotine. The goal of the experiments in Chapter 5
was to investigate these possibilities in the male sex. Some studies have shown that
adolescent nicotine exposure has important molecular consequences. Schochet et al.
(2005) have shown that while nicotine exposure in general upregulates genes such as cfos, only adolescent nicotine exposure causes changes in levels of arc mRNA in the
PFC. Data from Azam et al. (2007) has shown that α5, α6, and α7 mRNA levels peak
during adolescence before decreasing to a steady level in adulthood. This same study
also demonstrated that there are regional differences in expression of α5, α6, and β3
mRNAs with elevated levels in the substantia nigra as compared to the ventral
tegmental area. It is clear that nicotine can have significant effects on brain
development and maturation particularly during the adolescent period. Yet a full
understanding of receptor regulation and function is still lacking. Our research aimed to
contribute to the knowledge of the effects and to link molecular mechanisms to our
behavioral observations.
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Our results show that in four brain regions (striatum, cortex, hippocampus, and
thalamus) nAChR function was enhanced in the adolescent as compared to the adult
using a rubidium efflux assay. Since these results could be due to several factors
including the hypothesis that there is a greater quantity of basal nAChRs in adolescent
mice, we sought to answer this question by using receptor binding studies. Using
various pharmacological tools, our data reveal no significant differences in total nAChR
binding or binding for any specific nAChR subtype. Since the previous study by Azam
et al. (2007) found differences in mRNA levels for several nAChR subtypes, this was a
surprising result. However, disparities in mRNA levels do not always translate into
changes in receptor expression therefore results must be interpreted with caution. In
addition to receptor binding, we also investigated nicotine-induced dopamine release
from striatal synaptosomes. Again, in contrast to previous findings (Azam et al. 2007),
we did not see any significant differences in dopamine release. Differences between
our study and the study by Azam et al., which may account for disparities in the
outcomes, include assay technique (microdialysis vs. synaptosomes in our study), age of
subjects (PND 7 and 14 vs. PND 28-30 in our study), and species utilized (rats vs. mice
in our study).
Importantly, we have shown that adolescent nAChRs exhibit increased function
when stimulated with nicotine. The precise reasons for this increase are yet to be
determined, but this functional response is likely to play a role in behavioral response to
nicotine. Indeed, this data correlates well with an enhanced responsiveness in the CPP
model. However, it does not correlate with the data from our acute studies in which
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adolescent and adult male mice displayed no significant differences in three out of four
measures in responses to acute nicotine. It may be that differences in the biochemical
measure are not enough to reach behavioral thresholds in a model using short exposure
to nicotine such as that in our acute studies. However, a sub-chronic or chronic dosing
protocol, such as that used in CPP, is enough to surpass this threshold which is why
differences are seen using this model.
This increase in nAChR function is not attributable; however, to an increase in
the number of basal nAChRs during the adolescent period, despite previous data
indicating an increase in mRNA expression for certain receptor subtypes (Azam et al.
2007). We have also shown that dopamine release from the striatum does not differ
between adult and adolescent mice; a finding in contrast to results in the previously
mentioned study done in rats. It is likely that an increase in nAChR function causes
alterations in downstream effectors which may play an important role in the behavioral
differences. Specific possibilities will be further discussed in the future directions
section of the discussion.
E. Exposure to nicotine during early adolescence has persistent effects on nicotine
dependence in adulthood
The third specific aim of this dissertation was to examine the effects of
adolescent nicotine exposure on long-lasting nicotine dependence. Clinical studies
suggest that the earlier a person begins smoking, the more likely it is that he will
develop a lifetime dependence on nicotine (Kandel and Chen 2000; Chassin et al.
1990). Several studies in rats have shown that adolescence is a critical period, but to
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our knowledge, no studies in mice have been conducted. In addition to developing
these models in another species, we sought to examine the effects of dose, exposure
duration, and phase of adolescence in models of nicotine reward and withdrawal.
Using the CPP model as an indication of nicotine reward, we found that male
adolescent mice exhibited enhanced rewarding effects in a dose- and durationdependent manner. That is to say, a repeated adolescent nicotine exposure pattern (7
days) and a higher dose of nicotine (0.5 mg/kg) resulted in elevated reward levels in the
CPP model when mice were tested in adulthood. Moreover, this result was unique to
mice exposed during early adolescence (PND 22-28) and was not seen when mice were
exposed to nicotine during late adolescence (PND 50-56) or adulthood (PND 71-77).
These same parameters were also used to assess adolescent nicotine exposure on
withdrawal in adulthood. Similar to the reward model, we observed that early
adolescent nicotine exposure caused a long-lasting attenuation of both somatic and
affective withdrawal signs in adulthood. In contrast to our reward studies, intensity of
withdrawal signs decreased in adulthood after both short- (3 day) and long-term (7 day)
nicotine exposure. In addition, both high (48 mg/kg/day) and low (24 mg/kg/day) doses
of nicotine produced this reduction. Late adolescent and adulthood mice tested in this
paradigm did not show diminished withdrawal signs when evaluated in adulthood again
supporting the hypothesis that early adolescence is a particularly distinctive period for
the development of nicotine dependence.
Taken together, these studies confirm that early adolescent nicotine exposure
results in long-lasting alterations in the behavioral response to nicotine. The rewarding
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effects of nicotine are elevated in a dose- and duration-dependent manner, while
nicotine withdrawal signs are attenuated independently of these factors. Our findings
suggest that children and teenagers who begin smoking cigarettes at a young age are
likely to have long-term consequences as a result of this behavior. Moreover, certain
aspects of dependence can be observed after short exposure periods and exposure to low
doses of nicotine. Indeed, in the clinical setting, studies indicate that dependence can be
seen after smoking only a few cigarettes (DiFranza et al. 2002, 2007). Correlating this
to a rodent model, significant upregulation of nAChRs was found after exposure to low
doses of nicotine corresponding to a net consumption of just two cigarettes a day (after
correction for species differences) (Lichtensteiger et al. 1988; Trauth et al. 2000). In
summary, both animal models and human studies suggest that early age
experimentation with cigarette smoking could have important implications on future
nicotine dependence.
These findings also raise the question of how second-hand smoking effects in
adolescence may affect levels of nicotine dependence. We have shown that relatively
short periods of nicotine exposure and at low levels may cause alterations in important
regulatory systems. Children who have parents or friends who smoke may be exposed
to levels of nicotine which could detrimentally effect the development of neurological
systems. These changes are likely to affect the reinforcing and aversive properties of
nicotine and other drugs of abuse and may lead to increased vulnerability in these areas.
In order to gain a more complete understanding of these possible consequences, studies
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examining the effects of passive exposure to nicotine on later susceptibility to nicotine
dependence should be conducted.
F. Exposure to nicotine during early adolescence has persistent effects on cocaineinduced behavior in adulthood.
Nicotine is one of the first and most commonly abused drugs in adolescence and
is known to be a strong predictor of subsequent alcohol and other drug abuse (Kandel et
al. 1992). Indeed, our data demonstrate the effects of adolescent nicotine exposure on
cocaine-induced behavioral responses. We show that early adolescent nicotine
exposure can enhance the rewarding effects of cocaine, cocaine-induced hyperactivity,
and behavioral sensitization to cocaine. In both our CPP model and our acute
locomotor studies, data showed that a repeated exposure to the higher dose of nicotine
(0.5 mg/kg) was able to alter cocaine-induced responding. In contrast, neither acute
exposure nor a low dose of nicotine (0.1 mg/kg) was able to elicit this effect. These
findings have important implications for cross-sensitivity between nicotine and cocaine.
It is likely that the mechanisms behind dependence to these two drugs share some
commonalities.
Although drugs of abuse target several brain areas, enhanced dopamine
transmission from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) is
a key element in the reward (Koob and Le Moal 1997; Dani 2003). It is known that
adolescent nicotine exposure has long-lasting effects on the development of various
pharmacological systems and it is likely that the dopaminergic system is one which is
greatly affected.

Since nicotine and cocaine are both known to effect levels of
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dopamine in the brain, this pathway is a likely candidate for the observed crosssensitization.

Although our data in Chapter 5 did not find significant differences

between adults and adolescents in nicotine-induced dopamine release, it was not done
after repeated exposure to nicotine. Therefore, it is still possible that dopamine plays a
role in these changes. Furthermore, our technique used synaptosomes which are a crude
preparation that does not preserve the intact neuronal connections between cells. It is
possible that more precise techniques such as microdialysis would be more useful in
this regard.
Other receptors may also be involved in our behavioral observations. Indeed,
glutamatergic receptors are known to be involved in nicotinic effects as well. Adriani
et al. (2004) demonstrated that adolescent, but not adult, nicotine exposure downregulated mGluR2/3 subunits in the hippocampus and striatum. This same study also
showed changes in NMDA NR2A/B subunits regardless of the time of exposure
suggesting the involvement of NMDA receptors in certain aspects of nicotine
dependence. These findings imply that other receptors may also be involved and should
be further examined.
G. Conclusions and Implications
In summary, the research in this dissertation contributes to the further
understanding of several components adolescent nicotine dependence. We are the first
group to undertake a comprehensive study of nicotine reward and withdrawal
investigating both age- and sex-related effects. In addition, we have established the role
for a variety of factors such as dose, sex, and duration of exposure period. We have

156
found that adults and adolescents differ in their response to nicotine in both reward and
withdrawal models. In addition, we have shown that males and females display
opposing trends in these models. These data implicate the need for specifically targeted
smoking cessation therapies in order to effectively reduce the number of unsuccessful
quit attempts.
Our research has also shown that there in an increase in nAChR function in the
adolescent rodent upon nicotine stimulation. This increase is function is not attributable
to an increase in the basal number of receptors, but may involve other receptor
regulation mechanisms such as desensitization or upregulation. Moreover, adolescent
nicotine exposure also significantly enhances nAChR in adulthood, even after a drugfree period.
Finally, we have demonstrated in a mouse model that relatively low levels and
short exposure to nicotine during adolescence has long-lasting effects on both nicotine
and cocaine dependence in adulthood. Specifically, early adolescence represents a
particularly unique period of development which is susceptible to these effects, while
middle and late adolescent ages do not appear as critical. Our data show that adolescent
nicotine exposure causes enhancement in both nicotine and cocaine-induced reward.
Furthermore, these effects are dependent on the dose and duration of exposure. In
contrast, adolescent nicotine exposure causes attenuation of nicotine withdrawal
independent of treatment duration and dose. Nicotine treatment in early adolescence
also elevated cocaine-induced hyperactivity and locomotor sensitization further
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indicating its ability to induce neurochemical changes which alter susceptibility to drug
dependence well in adulthood.
H. Future Studies
Studies indicate that nicotine, like cocaine, activates the mesocorticolimbic
dopamine system suggesting that these two drugs of abuse share similar neurological
mechanisms. Indeed our research shows that nicotine exposure is able to enhance the
several effects of cocaine later in life. This data is novel and intriguing and has
substantial implications in regards to adolescent smoking.
In our studies, relatively low levels of nicotine and short patterns of exposure
were utilized demonstrating that even experimentation with cigarette smoking could
have significant consequences. A study by Damaj et al. (2007) has shown that 60 min
following a 2.5 mg/kg administration (s.c.) of nicotine the plasma level was
approximately 40 ng/ml. Our study used a dose of nicotine five times lower than that in
the previous study (0.5 mg/kg). Since the dose and plasma nicotine levels are linearly
correlated (Lichtensteiger et al. 1988), this would indicate a plasma nicotine level of
approximately 8 ng/ml in our experiments after 60 min. In addition, the maximal
plasma level of nicotine (Cmax) was equal to 314 ± 170 ng/ml in the study by Damaj et
al. (2007). We would therefore expect a maximum plasma nicotine level in our study to
be approximately 63 ng/ml. Our studies exposed animals to nicotine levels that are
three times lower than the plasma nicotine levels reported for a typical smoker (25
ng/ml (Trauth et al. 2000)). Taken together, our findings show that short exposure to
relatively low levels of cigarette smoke is likely to have detrimental and long-lasting
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effects on drug dependence. Though this is the first study to examine these factors in
the mouse model, our findings are in agreement with a study in adolescent rats which
also found that the biological mechanisms underlying nicotine dependence can be
activated by nicotine exposure comparable to that of an occasional smoker (AbreuVillaca et al. 2003).
The mechanisms which underlie this “cross-sensitization” are still being
elucidated. However, several future studies would be useful in determining these
pathways. For example, nicotine may be altering dopamine receptor number or
function or the level of dopamine transporters; therefore studies which measure DA
receptor function and binding of DA ligands as well as DAT binding should be
conducted. Specifically, D1 and D2 ligands are of particular interest. Functional assays
such as GTPγS autoradiography would be a useful in vitro strategy in this regard.
Moreover, studies have shown that there is an age-dependent development of
dopaminergic receptors in that levels peak in adolescence before declining to adult
quantities (Brenhouse et al. 2008). These changes in receptor quantity correlate with
cocaine-induced responding in models such as conditioned place preference. The use of
DA receptor agonists and antagonists may also contribute to further understanding. For
example, agonists have been shown to enhance the rewarding effects of cocaine in
juveniles which previously did not show cocaine preference (Brenhouse et al. 2008).
The use of DA ligands may prove useful in smoking cessation treatment strategies and
should be further explored.

159
Based on our findings, future studies should focus on a repeated exposure
pattern during the early adolescent period. Our data showed that acute exposure was
not sufficient to induced persistent behavioral alterations. It is likely that this exposure
pattern is not able to activate important downstream effectors which contribute to these
alterations. Recruitment of proteins involved in synaptic plasticity or gene expression
are most likely required to induce such results. In summary, we are the first to see that
after relatively short exposure periods of low doses of nicotine, there are long-term
changes in the behavioral responses to cocaine. One particular challenge in explaining
these findings is identifying fairly stable drug-induced changes which correlate to these
behaviors. These types of alterations would add to the comprehension of our results.
Several factors may be contributing to our observations and should be further
explored. Differences in memory storage, synaptic plasticity, and gene transcription
and expression should all be considered. We have shown that there is increased nAChR
function in both naïve adolescent synaptosomes and in adult synaptosomes following
adolescent nicotine exposure. This increase in receptor function may translate into
downstream consequences which may be more directly involved in the plasticity
effects. In addition to changes in the dopaminergic system which have been previously
discussed, it is important that other alternatives are considered.
Certainly, long-term effects may be mediated by drug-induced changes in gene
expression. Given that the adolescent period is known to be a highly malleable phase of
development in which there is an elevated level of synaptic remodeling (Rakic et al.
1994), it is probable that exposure to drugs of abuse is able to transform circuitry in the
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brain and induce transcription factors which cause further long-term effects. Two
transcription factors that have been strongly implicated in the addictive properties of
drugs of abuse are CREB (cAMP response element binding protein) and ∆FosB.
Nicotine has been shown to induce the transcription factor ∆FosB, a member of
the Fos family of transcription factors (Pich et al. 1997). ∆FosB is a good candidate for
causing long-term plasticity effects in that it is rapidly induced, but is also very stable
due to its long half-life (Chen et al. 1997). Studies with transgenic mice have allowed
researchers to investigate the role of this transcription factor in the behavioral plasticity
to drugs of abuse. In particular, a study by Kelz et al. (1999) found that mice
overexpressing ∆FosB showed enhanced sensitivity to both acute locomotor effects and
rewarding effects of cocaine. Indeed, an upregulation of ∆FosB due to adolescent
nicotine exposure would explain our results which also demonstrated enhanced
responding to cocaine’s acute and rewarding effects.
In addition to research showing that nicotine is able to induce ∆FosB, there is
also other evidence which may link this transcription factor with our data. ∆FosB is
likely to act at other targets which play a role in nicotine and cocaine addiction. For
example, the study by Kelz et al. (1999) also indicates that the GluR2 subunit of the
AMPA receptor is a target of ∆FosB. Furthermore, they show that GluR2 expression is
increased in the NAc following overexpression of ∆FosB. This study goes on to
eloquently show that rewarding effects of cocaine are enhanced due to overexpression
of the GluR2 subunit which gives another possible mechanism that would explain the
data presented in Chapter 7. Since induction of ∆FosB is long-lived, but not
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permanent, the upregulation of receptor subunits such as GluR2 in the AMPA receptor
help to better explain why adolescent drug exposure may have effects of further drug
abuse well into adulthood.
Other possible transcriptional mechanisms which should be considered when
explaining our results is the induction of CREB by nicotine. Several studies have
demonstrated a correlation between nicotine administration and CREB. In particular,
Walters et al. (2005) have shown that activation of CREB is necessary for nicotine
reward in adult mice as measured by conditioned place preference testing. Furthermore,
chronic nicotine administration in mice results in decreased CREB phosphorylation in
the NAc but increased CREB phosphorylation in the prefrontal cortex, while nicotine
withdrawal increases CREB phosphorylation in the VTA (Brunzell et al. 2003). In
contrast, another study shows that withdrawal from chronic nicotine in rats decreases
CREB, phosphorylated CREB, and CRE-DNA binding in the cortex and amygdala
(Pandey et al. 2001). While the precise role of CREB is not yet determined, it is clear
that it is involved in both nicotine reward and withdrawal. Induction of the
transcription factor CREB has been linked to an increase in the expression of tyrosine
hydroxylase (Piech-Dumas and Tank 1999), an enzyme which is critically involved in
the formation of dopamine. Even though the induction of CREB is relatively shortlived as compared to that of ∆FosB, it may still play a role in long-term plasticity
changes via the enhancement of dopamine in the mesolimbic reward pathway.
In summary, it is probable that transcriptional mechanisms such as the ones
described above are involved in the long-term plasticity effects of adolescent nicotine
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exposure. It will be worthwhile to explore these mechanisms in greater detail in the
future. Studies involving transgenic mice (both CREB and ∆FosB) as well as an
investigation of pCREB and ∆FosB markers through molecular techniques such as
western blots could add to the understanding of the behavioral results which are
described in our research.
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